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ABSTRACT
ALTERNATIVE METHODS OF THE TREATMENT OF CHEMO-RESISTANT
CANCERS
MAY 2016
KAITLYN E. WONG B.S., STATE UNIVERSITY OF NEW YORK AT STONY
BROOK
M.P.H., TUFTS UNIVERSITY
M.D., TUFTS UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sallie S. Schneider

Great strides have been made in cancer therapy in the past century, yet it remains
one of the leading causes of death in the United States today. This work aimed to shed
light on novel methods to treat a variety of aggressive and often chemo-resistant cancers
both in vitro and in vivo.
The first aim of this work was to evaluate the therapeutic efficacy of poly
(methacryloyloxyethyl phosphorylcholine) (polyMPC) prodrugs compared to standard
chemotherapeutic agents. Conjugation of polyMPC to drugs such as doxorubicin (Dox)
can result in its improved solubility, prolonged half-life and therapeutic efficacy.
PolyMPC and polyMPC-Dox (at a dose less than 10mg/kg) was observed to be safe for
systemic administration in a murine model. Additionally, treatment with polyMPC-Dox
resulted in improved survival and reduced off target toxicities in mice with orthotopic
human ovarian xenografts. Further, mesenchymal stem cells (MSCs) were observed to
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successfully uptake polyMPC and home to breast cancer xenografts in vivo and thus can
potential serve as a vehicle to improve drug delivery.
Additional aims of this work focused on evaluating the root extract of Rhodiola
crenulata (RC) plants for the treatment of aggressive cancers derived from the neural
crest, including neuroblastoma and melanoma. RC was observed to reduce growth and
migration of melanoma in vitro. Further, RC resulted in reduction of aggressive tumor
characteristics upon topical therapy as well as the reduced establishment of metastatic
foci upon enteral administration in mice with melanoma. While no difference in
outcomes was observed upon RC treatment in a disseminated neuroblastoma model in
vivo, RC did result in striking cytotoxic effects upon treatment of neuroblastoma cells in
vitro. These cytotoxic effects of RC likely resulted from derangements altering the cell’s
ability to undergo optimal cellular metabolism.
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CHAPTER 1
INTRODUCTION

1.1 Significance
Cancer remains a critical public health concern as it continues to be one of the
leading causes of death, not just in the United States, but throughout the world. The
American Cancer Society projected that more than 1.6 million new cancer diagnoses,
excluding basal and squamous skin cancers and non-invasive in situ cancers, were
diagnosed in 2015 in the United States [1]. Further, more than half a million deaths in the
Unites States were a result of cancer in 2015 [1]. Only heart disease and accidental
trauma results in more deaths than cancer, in adults and children respectively, in the
United States annually. There is a greater than 38% lifetime risk (38% female, 43% male)
of developing cancer in the average American [1]. While significant improvements in
detection and treatments for cancer over the last few decades have resulted in the
downward trend of the incidence of cancer and death resulting from this disease [2], still
it contributes a significant burden to the health care of our society.
Evaluation of novel methods to not only treat cancer but to improve currently
available therapeutic options can enhance treatment efficacy and result in improved
patient outcomes and survival. The research presented in this thesis seeks to evaluate
polyMPC polymer prodrugs and Rhodiola crenulata (RC) plant extracts for the treatment
of a variety of chemo-resistant cancers both in vivo and in vitro.
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1.2. Current Cancer Therapeutic Strategies
The treatment of cancer, depending on the stage of the disease at presentation,
often requires a multidisciplinary approach to therapy combining medicine, surgery and/
or radiation. While surgery and radiation are more loco-regional based efforts of
treatment, chemotherapeutic drugs, typically provided systemically, are utilized in more
invasive and disseminated stages of disease [3]. A variety of classes of chemotherapeutic
agents are available, many of which non-specifically target rapidly growing and dividing
cells, including cancer cells. These drugs are also associated with severe side effects
related to dosing, biodistribution and the pharmacokinetics of these agents. While side
effects can be as generalized as fatigue and gastrointestinal complaints, specific drugs can
result in significant toxicities, resulting in devastating morbidities such as cardiac, renal
or neurotoxicities [3]. The severity of these side effects can limit optimal dosing or even
the utilization of these agents entirely despite their potential therapeutic benefit.
Investigation into novel agents and means to improve current therapy is ongoing.
Novel treatment classes, such as immunologic agents, have been developed. These agents
enhance immune function, promoting both innate and adaptive immunologic anti-tumor
defenses [4]. Additionally, genetic and proteomic profiling have also been evaluated to
optimize therapy for each patient based on their specific tumor characteristics.
Investigation also continues to identify naturally available treatment agents, such as
bioactive fractions of plant based phytochemicals that may provide us with novel
treatment or preventative agents. Finally, additional strategies to improve traditional
chemotherapeutic agents have also been employed. A variety of methods have been
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utilized to improve tumor targeting and drug delivery through both active and passive
mechanisms, thus improving the efficacy and tolerance of these agents.

1.3 Polymer Based Therapeutic Agents
The creation of prodrugs is one method to improve the effectiveness of available
chemotherapeutic agents. Prodrugs are created through the modification of drugs by
means of binding biologically inactive moieties to these agents to alter their biologic
properties upon administration in vivo [5]. When administered systemically, the drug is
often inert given it’s attachment to the bound chemical molecules. The prodrug can be
modified by a variety of means, including enzymatic and chemical modifications, in
order to release the drug in its active form and at the optimal site of action, such as within
a tumor. The goals of utilizing prodrugs are to increase drug uptake by tumors and reduce
unintended uptake of these drugs by other organs [4-6]. Utilization of prodrugs can allow
for improved drug tolerance through allowance of higher drug administration or through
reduction of harmful side effects that could limit drug tolerance.
The chemical moieties employed to create prodrugs can also allow for improved
pharmacokinetic and biodistributive profile as the utilized scaffolds can improve drug
solubility and half life of the index agent. Further, improved tumor uptake of the drug in
prodrug form can result secondary to the enhanced permeability and retention (EPR)
effect. This effect states that larger and bulkier molecules bound to drugs are more likely
to be taken up by the leaky, disorganized vasculature of the tumor micro-environment
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[6-9]. Uptake is further enhanced secondary to its prolonged circulation and decreased
rate clearance provided by the conjugation of these drugs to polymers.
A variety of polymer nanocarriers, such as poly(ethylene glycol) (PEG) have been
utilized for prodrug creation [4-6]. Several strategies are utilized to create prodrugs using
polymers in which the drug can be conjugated to a preformed polymer, the drug can be
bound to a monomer prior to polymerization or polymerization can be initiated following
binding to the agent of interest [5]. Utilization of polymers as a means to create prodrugs
provide several benefits as the synthesis of these facile molecules can be tailored in a
variety of ways including shape, size and drug binding capacity allowing for alterations
of drug availability and release. Investigation into alternative polymers, such as poly (2methacryloyloxyethyl phosphorylcholine) (polyMPC), can result in more efficacious and
potentially better tolerated prodrugs [7-8].

1.4 Drug Delivery Vehicles
In order to further enhance drug delivery, additional means to deliver treatment
agents are necessary. A variety of “carriers” have been evaluated as vehicles for drug
delivery to improve targeting of drugs, such as liposomes or polymer micelle
formulations [5,6,9]. These vehicles serve to not only shield drugs while in systemic
circulation, thus preventing unintended exposure of these agents to certain tissues, but
can also result in improved drug targeting specifically within the tumor bed. Several
clinically relevant drug formulations employ these techniques. For example, doxil is a
liposomal formulation of the anthracycline agent, doxorubicin (Dox) [10,11]. Through
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utilization of a liposomal carrier, Dox uptake within the tumor is enhanced and it’s uptake
in cardiac tissues is reduced, resulting in improved therapeutic efficacy and less
cardiotoxicity [11].
Active targeting methods often employ ligand mediated targeting whereby
ligands, such as antibodies, which are specific for cell surface molecules or receptors on
tumors are bound to drugs resulting in very specific interactions required for drug
delivery [6]. Alternative methods can also be utilized to further deliver drug directly to a
tumor. Cellular vehicles hold promise as an alternative and potentially active means to
promote drug delivery. A variety of cells including T-cells, macrophages and stem cells
are known to have inherent migratory and tumoritropic abilities. The micro-environment
of tumor stroma is similar to that of a healing wound and thus releases chemoattractant
molecules which stimulate the migration of these cells to tumors. Mesenchymal stem
cells (MSCs) are pluripotent progenitor cells with tumoritropic characteristics that are
found throughout the body [12-16]. The therapeutic advantages of these cells have
already been harnessed clinically, given their attraction to sites of injury, in order to treat
tissue damaged from myocardial infarctions and strokes [17,18]. The tumoritropic
properties displayed by MSCs can be taken advantage of therapeutically, as MSCs can be
physically or genetically modified to deliver drugs or anti-cancer agents directly to
tumors.

1.5 Phytochemicals and Cancer Therapy
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Natural products are agents derived from plants, animals and microbes that are
potentially biologically and pharmaceutically active [19-21]. Almost a quarter of novel
drugs developed for cancer treatment between 1981-2002 were composed of, derived
from or were discovered in natural agents [20]. Many continue to remain under
investigation, and are even undergoing evaluation in active clinical trials.
Phytochemicals, or natural agents derived from plants, comprise a significant proportion
of the products. Many phytochemicals are used for both the prevention or treatment of
cancer [19-22]. There are four classes of plant based compounds that are currently
utilized clinically for the treatment of cancer including vinca alkaloids,
epipodophyllotoxins, taxanes, and camptothecins [21]. While phytochemicals are one of
the key sources of agents utilized to treat cancer, still many of these plant based agents
have yet to be evaluated critically for their ability to treat cancer or provide insight into
potential novel targets for cancer therapy.
Bioactive fractions from a variety of dietary plants or plant extracts have been
utilized in traditional medicines for centuries and are known to treat or prevent the
development of cancer. These agents can be derived from a vast array of plants, including
licorice, ginger, green tea, as well as many others [21]. These plant based products result
in the prevention or treatment of cancer through a variety of mechanisms. Several of the
means to which these phytochemicals result in anti-tumorigenic effects on a wide array of
cancers (either in vitro or in vivo) include anti-inflammatory and pro-apoptotic properties,
prevention of cellular epithelial to mesenchymal transitions, as well as prevention of
metastatic spread and establishment [20,22].
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Rhodiola plants have been utilized medicinally for centuries in Eurasian cultures.
The genus Rhodiola is composed of nearly 90 different species of plants which grow
throughout Eastern Europe and Asia [19,23]. Rhodiola plants grow throughout regions of
high altitude, cold climates and barren soil. Given this, these plants have evolved to
produce a numerous adaptogenic compounds which allow the plant to thrive in such
harsh environments. Many of the fractions of Rhodiola plants that display medicinal
properties, such as salidroside, tyrosol, caffeic acid, rosin and rosavin, are classified as
adaptogens as the are utilized to prevent the effects of cellular stressors [19,23-29]. Today
Rhodiola extracts are available as a natural supplement used for the treatment of fatigue,
depression, anemia, impotence, gastrointestinal ailments, infections, and nervous system
disorders. These extracts are believed to convey improved physical endurance and boost
the immune system [19,24-29]. Extracts from Rhodiola crenulata (RC) are known to be
bioactive and bioavailable and are under investigation as a therapy in several types of
cancers, including breast and bladder cancer [24-29]. RC extracts, and the compounds
contained within it, have the potential to serve as a novel adjunct for the treatment of a
variety of cancers.
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CHAPTER 2
EVALUATION OF POLYMPC PRODRUGS IN A HUMAN OVARIAN TUMOR
MODEL

This research was performed in close collaboration with Matthew Skinner and Dr.
Carmen Mora.

2.1 Introduction
Ovarian cancer is the most lethal gynecological malignancy among women in the
United States, and remains a leading cause of death with approximately 22,000 diagnoses
and 14,000 deaths annually [1]. Early tumor detection is challenging, and patients often
present with advanced, metastatic or disseminated disease at diagnosis. Conventional
treatment involves surgical de-bulking of solid tumor accompanied by chemotherapy.
Doxorubicin (Dox), an anthracycline chemotherapeutic, is a prominent treatment option
for various hematologic cancers and solid tumors, including malignant ovarian neoplasms
[2,3]. While Dox is a powerful anti-tumor agent, its efficacy is limited by rapid clearance
kinetics and non-specific accumulation in healthy tissue. This poor specificity leads to
off-target toxicity that causes myelosuppression, gastrointestinal irritation, and
cardiotoxicity, thus limiting Dox dosing even when its use is effective for tumor
reduction [2,4].
To improve the therapeutic efficacy of Dox, specifically its pharmacokinetics,
conjugation to polymers offers a convenient and attractive strategy. Polymer-drug
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conjugation produces prodrugs of larger hydrodynamic size than the drug alone. This
lengthens renal clearance half-life and prolongs in vivo circulation [5]. Coupling this
improved pharmacokinetic profile with the enhanced permeability and retention (EPR)
effect, whereby polymer-drug conjugates penetrate into the leaky vasculature of tumors
and become entrapped due to poor tumoral lymphatic drainage, drug uptake in solid
tumors is enhanced and off-target organ accumulation is reduced [6-8]. For ease of
delivery, hydrophilic polymers solvate otherwise water insoluble drugs at high loadings
[9-11], and are potential replacements for other excipients, such as ethanol, which are
problematic in some patient populations as they can cause severe or even fatal
anaphylactic reactions [12-13].
Poly(2-methacryloyloxyethyl phosphorylcholine) (polyMPC) [14-15], is a
hydrophilic polymer noted for its exceptional water solubility and biocompatibility
[16-18]. Dox conjugation to polyMPC was achieved by formation of hydrazone bonds,
which are acid-sensitive and thus cleavable in vivo. Previous evaluation of polyMPCDox prodrugs exhibited an in vivo circulation half-life of greater than two hours. Upon
evaluation of polyMPC-Dox treatment on an aggressive mouse breast tumor model (4T1
cell line), it’s administration reduced the mean tumor size and resulted in a two-fold
increase in survival time over free Dox treated mice. Dox in the prodrug animal group
accumulated in tumors at twice the level of that observed in mice treated with free Dox.
A corresponding reduction in off-target organ uptake was also observed.
To gauge the therapeutic breadth and clinical relevance of polyMPC-Dox, it’s
efficacy was evaluated in human cancer through utilization of the SKOV-3 ovarian tumor
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model in vivo. Experiments were performed with polyMPC and polyMPC-Dox to
evaluate it’s in vivo biocompatibility and establish a maximum tolerated dose (MTD) of
the prodrug. Mice with subcutaneously established SKOV-3 xenografts were treated with
Dox, polyMPC-Dox or Doxil, an alternate liposomal Dox formulation [2], using a
recurring dosing schedule resembling that employed for human patients [19]. Animals
were monitored for symptoms of treatment associated toxicity, change in tumor size, and
survival. The overall accumulation of Dox and polyMPC-Dox in solid ovarian tumors
was compared, as was the specificity for uptake in tumor tissue versus off-target organs.

2.2 Materials and Methods
2.2.1 Cell Culture.
Human ovarian adenocarcinoma SKOV-3 cells were maintained in Roswell Park
Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum,
100U/mL penicillin, and 100µg/mL streptomycin at 37oC under 5% CO2 (Thermo fisher,
Grand Island, NY).

2.2.2 Maximum Tolerated Dose of polyMPC and polyMPC-Dox.
The MTD of the polyMPC scaffold carrier and polyMPC-Dox prodrug were
evaluated in seven week old non-obese diabetic severe combined immunodeficient (NOD
SCID) mice, as they are commonly utilized for human tumor xenograft models [20, 21].
In order to evaluate the MTD of polyMPC, three mice per treatment group were
administered two doses of polyMPC dissolved in Hank’s balanced salt solution (HBSS,
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Thermo fisher, Grand Island, NY) at doses of 50, 100, 200, 400 or 800 mg/kg via lateral
tail vein injections administered on day 0 and day 17. The MTD of polyMPC-Dox was
evaluated both via intraperitoneal and intravenous administration. Three mice per
treatment group were administered a single dose of polyMPC-Dox in solutions of Dox
equivalent doses of 10, 20, 30, 40 or 50 mg/kg administered via a single lateral tail vein
injection or intraperitoneal injection.
Weight, appearance and behavior of the mice were monitored daily for a total of
35 days. Symptoms of toxicity were defined as weight loss greater than 15% or evidence
of distress in appearance or behavior. Animals exhibiting these criteria were euthanized
prior to the end of the study. At the completion of the study, all remaining mice were
euthanized and necropsy was performed to collect tissues for histologic evaluation

2.2.3 Biodistribution.
The uptake and accumulation of Dox within tumor tissue and off-target organs
was evaluated in four week old NOD SCID mice following treatment with either free
Dox or polyMPC-Dox. SKOV-3 ovarian human adenocarcinoma subcutaneous
xenografts were established following injection of 1x107 cells in the right flanks of nine
mice. Following tumor establishment and growth to a volume of 100-500mm3 (calculated
by length X width2⁄2), three mice per treatment group were administered HBSS,
polyMPC-Dox (6 mg/kg Dox equivalent) or free Dox (6 mg/kg) via lateral tail vein
injection. Three days following the injections, mice were euthanized and organs (liver,
kidneys, spleen, heart, lungs) and tumor were resected, weighed, and then flash frozen in
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liquid nitrogen. All tissues were stored at -80°C prior to analysis. Dox accumulation in
the resected tissues was assessed by HPLC and normalized to HBSS values in order to
determine Dox concentration.

2.2.4 Tumor Efficacy.
The therapeutic efficacy of polyMPC-Dox was evaluated using a human ovarian
tumor model in NOD SCID mice. Human ovarian tumors were established by injecting
1x107 SKOV-3 cells subcutaneously in the right flanks of 24 four week old NOD SCID
mice. Mice identified to have intramuscular tumors were excluded from analysis. Once
tumors reached a volume of 250-500 mm3, mice were randomly divided into four
treatment groups of 7-8 mice. Treatment groups included: HBSS (control), 2mg/kg free
Dox (half of the reported Dox MTD in NOD SCID mice) [23], polyMPC-Dox at 5mg/kg
Dox equivalent dosing (half of the polyMPC-Dox MTD dose), and 5mg/kg Doxil (Dox
dose equivilant to polyMPC-Dox). Mice were administered treatment via lateral tail vein
injections every 7-8 days. Treatment was withheld if the animals exhibited significant
weight loss approaching 20% or excessive injection site wounds or scarring prohibiting
further injections.Animals were evaluated every 24-48 hours for overall health, tumor
volume and weight. Mice were removed from the study and euthanized if they
experienced weight loss greater than 20%, exhibited signs of distress or if tumor volume
exceeded 1500mm3. At time of euthanasia, necropsy was performed and tumors and
organs (liver, kidneys, spleen, heart and lungs) were collected for histologic evaluation.
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2.2.5 Statistical analysis
All graphs were were created and statistical analysis was performed using
GraphPad Prism Software (Prism, GraphPad Software, Inc., San Diego, CA).

2.3 Results
2.3.1 Maximum tolerated dose (MTD) of polyMPC.
For the entirety of the study, the polymer was well tolerated at all doses with no
physical or behavioral concerns for toxicity. All mice treated with polymer exhibited
weight gain similar to those of control mice (Fig 2.1A). Histological evaluation of the
heart, kidney, spleen and lungs resected from mice treated with polyMPC exhibited no
differences from the organs of the control animals. Livers of mice administered polyMPC
did exhibit an increase in lymphocyte concentration at higher polymer doses, however,
these changes were minor and were observed with no corresponding effect on the health
of the hepatocytes (Fig 2.1D).

2.3.2 MTD of polyMPC-Dox Establishment.
Mice were unable to tolerate polyMPC-Dox at all doses following intraperitoneal
administration secondary to weight loss and ill health necessitating euthanasia (Fig 2.1B).
Mice administered PolyMPC-Dox intravenously at doses of 20-50 mg/kg experienced
weight loss and required removal from the study by euthenasia. However, mice treated
with 10mg/kg polyMPC-Dox survived throughout the course of the study period with no
overt signs of systemic toxicity observed (Fig 2.1C). Histologic analysis of liver sections
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of mice administered intravenous polyMPC-Dox demonstrated evidence of lymphocytic
infiltration and hepatocyte enlargement otherwise no significant histologic changes were
observed upon polyMPC-Dox treatment (Fig 2.1D).

2.3.3 Biodistribution of PolyMPC-Dox in a human ovarian tumor model.
Three days after intravenous treatment of either polyMPC-Dox (Dox equivalent
dose of 6mg/kg) or free Dox (6mg/kg), the mean tumor uptake of polyMPC-Dox and free
Dox was 1120 ng/g and 567 ng/g of tissue, respectively. The accumulation of polyMPCDox in solid tumors was nearly two-fold that of free Dox after a single injection, resulting
in a significant difference of α=0.10 (p=0.064). However, no significant differences were
observed for polyMPC-Dox and free Dox accumulation in off-target organs.

2.3.4 Tumor efficacy.
The efficacy of polyMPC-Dox was evaluated using NOD SCID mice with
subcutaneously established SKOV-3 tumors. Following tumor establishment, one mouse
from the polyMPC-Dox group was excluded due to formation of an intramuscular tumor
which precluded accurate measurement of tumor volume. Mice administered HBSS alone
and polyMPC-Dox received a total of eight doses. Mice treated with free Dox received
6-7 doses of drug secondary to the development of ulcers in the tail at sites of drug
infusion which prevented administration of drug. Mice treated with doxil were only able
to tolerate 5-6 doses of drug given significant weight loss necessitating withholding drug
administration or euthanasia (Fig2.3B). The mean weight of mice treated with polyMPC-
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Dox and free Dox increased similarly to the control group. In contrast, mice treated with
doxil exhibited significant weight loss following drug administration (Fig 2.3C). By Day
50, seven of eight control animals were euthanized due to excessive tumor growth and as
a result, final treatments for all groups were administered at Day 53.
Mice treated with polyMPC-Dox exhibited mean survival time of 79 days, almost
twice that of the control mice of 47 days, 15 days longer than the mean survival of mice
treated with free Dox (~64 days) and 40 days longer then mean survival of mice treated
with doxil (~38.5 days) (Fig 2.3A). Moreover, by Day 60, all control mice had been
euthanized, 86% of the animals treated with polyMPC-Dox were still alive, 50% of the
mice from the free Dox group had survived and only 38% of doxil treated mice remained
alive. Overall survival of mice treated with polyMPC-Dox was 121 days, 35 days longer
than the free Dox group and 56 days longer then doxil treated mice. Treatment with
polyMPC-Dox reduced tumor growth compared to the free Dox and control groups. By
day 49 the increase in mean tumor volume for HBSS and free Dox groups was 1991%
and 1113% of the original tumor volume, respectively (Fig 2.3D) while the mean tumor
growth in the polyMPC-Dox group was 440% at Day 49. In contrast, the tumor volumes
of mice treated with doxil exhibited minimal growth by day 49 (~84% of initial tumor
volume).
Upon necropsy, the organs and tumors were weighed and evaluated for any gross
changes and H+Es of the organs were further evaluated to assess for off target toxicities.
Upon evaluation of the heart, mice treated with doxil were observed to have a
significantly larger heart size in proportion to overall weight. Histologic evaluation of
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heart sections for mice treated with free Dox, polyMPC-Dox as well as doxil showed
evidence of minor myocyte eosinophilic bands. The lungs of mice treated with doxil were
also noted to be significantly larger in proportion to the total animal weight. Upon
evaluation of the lung tissue in mice treated with doxil, foamy cells present within the
lungs were observed which were not identified in other treatment groups. Differences
were also noted between the proportional weights of the liver and kidneys of control mice
in mice treated with polyMPC-Dox. Histological review of liver sections from mice
treated with free Dox and polyMPC-Dox revealed evidence of enlarged hepatocytes,
increased mitotic activity and lymphocytic infiltration.

2.4 Discussion
This work is the first reported evaluation of a polyMPC cancer prodrug in a
human tumor model. We have shown that the polyMPC construct is a safe scaffold for
administration in vivo and therefore can be utilized for the creation of prodrugs, such as
polyMPC-Dox. The performance of polyMPC-Dox was then compared to that of free
Dox and doxil in a human ovarian tumor model to assess it’s toxicity, tumor
accumulation properties, and therapeutic efficacy. PolyMPC-Dox treatment resulted in
increased tumor uptake and improved survival compared to free Dox. Additionally,
polyMPC-Dox was observed to be better tolerated then doxil, resulting in less systemic
toxicity.
The maximum tolerated dose is the greatest amount of drug that can be tolerated
without evidence of toxicity. All mice tolerated administration of polyMPC throughout
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the course of the study without any outward signs of weight loss or distress. Even mice
treated with a cumulative 1600mg/kg (800mg/kg per dose) of polyMPC exhibited weight
gain similar to that of HBSS control. Treatment utilizing higher doses of polymer were
unable to be performed given the high viscosity of the solution at polymer doses required
above 800mg/kg dosing. Upon gross inspection of internal organs following euthanasia,
there were no obvious abnormalities observed. Only the spleen and lung of mice treated
with 800mg/kg polyMPC exhibited a significant increase of the total percent body weight
of these organs. The livers of mice administered polyMPC exhibited an increase in
lymphocyte concentration at higher polymer doses, however, these changes were minor
and were observed with no corresponding effect on the health of the hepatocytes. This
study revealed that polyMPC is non-toxic even at very high doses. Further, this work
established the suitability of polyMPC as an injectable carrier for delivery of many types
of drugs.
Previously it was observed that polyMPC-Dox was well tolerated in athymic nude
mice at Dox equivalent doses greater than three-fold the reported MTD of 8 mg/kg for
free Dox [14,22]. NOD SCID mice, however, are known to be uniquely sensitive to Dox
[23], with systemic toxicity to Dox observed at doses as low as 4 mg/kg. Given this, an
MTD analysis of polyMPC-Dox was necessesary to re-establish the prodrug MTD
specifically in NOD SCID mice. At a dose of 10mg/kg DOX equivalent polyMPC-DOX,
mice were able to tolerate intravenous administration of the prodrug, although higher
doses of polyMPC-Dox were not tolerated. PolyMPC-DOX was not tolerated upon
intraperitoneal administration, potentially secondary to a more acidic environment found
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within the peritoneal fluid. This would result in disruption of the hydrazine linkage
binding Dox to polyMPC, resulting in a bolused release of free drug greater then it’s
MTD. Histologic analysis of liver sections of mice administered polyMPC-Dox
intravenously did demonstrate evidence of lymphocytic infiltration and hepatocyte
enlargement. However, as Dox treatment is commonly accompanied by hepatotoxicity,
these changes are most likely attributed to Dox itself [24,25]. Therefore the estimated
MTD of polyMPC Dox was an intravenous dose of 10mg/kg or lower in NOD SCID
mice.
The in vivo biodistribution of both polyMPC-Dox and free Dox was assessed in
mice bearing human ovarian tumors, comparing drug accumulation in tumor tissue and
off-target organs. Subcutaneous SKOV-3 tumors were established in the right flanks of
NOD SCID mice, and single doses of free Dox, at 6 mg/kg, or polyMPC-Dox at a Dox
equivalent dose of 6 mg/kg, were administered by tail vein injection. These selected
doses were consistent with previous biodistribution analysis of polyMPC-Dox in a breast
tumor model [15]. Three days after drug administration, mean tumor uptake of Dox was
observed to be increased in mice treated with polyMPC-Dox compared to that of free
Dox treated mice. No significant differences were observed for prodrug and Dox
accumulation in off-target organs. Improved drug uptake by mice treated with polyMPCDox can likely be attributed to the EPR effect or increased half life associated with
polyMPC conjugation to Dox.
The efficacy of polyMPC-Dox for treating a human cancer was evaluated using a
SKOV-3 ovarian tumor model. SKOV-3 tumors are Dox-resistant at dosing levels
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tolerated by animals [3], and thus this model allows for evaluation of polyMPC-Dox in a
challenging human tumor model. Approximately half the MTD was utilized for dosing of
free Dox (2mg/kg) and polyMPC-Dox (5mg/kg Dox equivilant). This was performed in
an attempt to minimize dose-limiting toxicity during the weekly dosing schedule
designed to mimic current clinical dosing practice [19]. Doxil, an alternative formulation
of Dox utilized clinical to treat a variety of cancers including ovarian cancer, is a
liposomal formulation of Dox. In order to compare the efficacy of polyMPC-Dox to an
alternate Dox formulation (Doxil), both drugs were administered at a Dox equivalent
doses (5mg/kg).
We observed that mice treated with polyMPC-Dox were able to tolerate more
frequent administration of drug compared to free Dox or doxil treated mice. Mice treated
with free Dox received between 12-14 mg/kg, mice treated with doxil received between
25-30mg/kg and mice treated with polyMPC-Dox recieved a total of 40 mg/kg
cumulative Dox over the course of this study. Further, multiple free Dox treated mice
developed local wounds overlying the site of tail vein administration which prevented
repeated drug administration. Only one mouse treated with polyMPC-Dox developed a
ulcer at the site of tail vein injection. In contrast, mice treated with doxil displayed
significant weight loss following drug administration approaching the 20% weight loss
cutoff necessitating euthanasia. Given the significant weight loss, additional drug
administration were withheld in these mice. In comparison, no significant weight loss
was observed in mice treated with HBSS, free Dox or polyMPC-Dox.
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Mice treated with polyMPC-Dox displayed improved survival compared to other
treatment groups. PolyMPC-Dox treated mice survived almost twice that of control and
doxil treated mice and approximately two weeks longer that of free Dox treated mice. In
addition to improved survival, treatment with polyMPC-Dox displayed a reduced rate of
tumor growth compared to free Dox and control groups. Tumors in mice administered
HBSS or free Dox grew slowly for 40 days, after which the tumor growth rate in both
groups rapidly increased most likely secondary to cessation of drug administration. The
rate of tumor growth in mice treated with polyMPC-Dox remained nearly stagnant for
approximately 80 days well beyond the final drug administration. In contrast, mice
treated with doxil did not exhibit any enlargement of tumor growth. Despite minimal
tumor growth, mice displayed significant weight loss and health issues, including hair
loss and abnormal gait, necessitating euthanasia much earlier then other treatment groups.
To assess systemic toxicity, the organs of animals were evaluated histologically to
assess for tissue damage. Upon evaluation of cardiac and lung tissues, we observed that
doxil treated mice had a significantly larger proportional weight of these organs.
Histologic evaluation of heart sections for mice treated with free Dox, doxil and
polyMPC-Dox only showed evidence of myocyte eosinophilic bands indicative of
ischemic changes in the cardiac tissue. Upon evaluation of the lung tissue, doxil treated
mice were observed to have foamy cells present within the lungs, secondary to the
presence of macrophages. These changes most likely are attributable to the development
of cardiac injury resulting in pulmonary edema and inflammation.
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Differences were noted between the proportional weights of the livers upon
treatment with free Dox and polyMPC-Dox were observed in which there was evidence
of enlarged hepatocytes, increased mitotic activity and lymphocytic infiltration indicative
of hepatotoxic injury. These findings were even more striking within the liver sections of
mice administered free Dox, which is consistent with the known hepatotoxic nature of
Dox [24, 25]. The changes observed in liver tissue, therefore, are likely attributable to
Dox itself, and not the prodrug or polymer carrier. Moreover, given the serial
administration of drug used in the efficacy study, accumulation of Dox in organs involved
in drug clearance would be expected resulting in observed histologic changes. Further
research is warranted to examine polyMPC-Dox clearance, especially under such
treatment conditions that resemble current clinical regimens.
Upon comparison of outcomes of the different treatment groups evaluated in the
efficacy study, polyMPC-Dox was the best tolerated Dox formulation allowing for the
most consistent administration of drug with minimal side effects. While comparable Dox
doses were provided upon each dose of polyMPC-Dox or doxil provided, significant
toxicities were observed both grossly and histologically in mice treated with doxil that far
outweigh the benefits of the the minimal tumor growth that it afforded. As NOD SCID
mice are exquisitely sensitive to Dox administration, it is possible that the liposomal
based Dox resulted in a bolused release of Dox systemically that exceeded the maximally
tolerated dose of Dox in animals. In contrast, polyMPC conjugation may have allowed
for a more gradual release and uptake within not just the tumor but off target organs, thus
resulting in improved drug tolerance and less side effects.
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2.5 Conclusion
Through this work, we not only established the safety of the polyMPC scaffold
for use in prodrug development but determined the efficacy of polyMPC-Dox prodrugs
through evaluation of it’s effect upon treatment in a human tumor xenograft in vivo.
PolyMPC itself was well-tolerated in NOD SCID mice, even at very high doses,
demonstrating its utility as an injectable polymer. Upon biodistribution analysis, Dox
accumulation from polyMPC-Dox treatment in the tumor tissue was nearly two-fold
higher then that of free Dox, without observation of enhanced uptake in off-target organs.
Toxicity and efficacy studies demonstrated that polyMPC-Dox could be administered to
mice at greater than twice the dose of free Dox without causing systemic toxicity.
Ovarian tumor-bearing mice receiving weekly prodrug dosing exhibited improved
survival time and reduced tumor growth relative to free Dox treatment. Additionally,
polyMPC-Dox treatments provided at the same Dox dose as doxil, was much better
tolerated and resulted in less systemic toxicity despite reduced tumor growth observed in
doxil treated mice. These results demonstrate the advantages of treating human ovarian
tumors using the polyMPC-Dox prodrug, including enhanced tumor uptake with reduced
off-target toxicity, higher dosing capabilities, and improved therapeutic efficacy. In vivo
evaluation in human ovarian tumors suggests that the polyMPC-Dox prodrug is safer and
more effective in the treatment of solid tumors compared to Dox or alternative Dox
formulations such as doxil. Thus, this study demonstrates the viability of polyMPC-Dox
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cancer therapy, and that a simple water-soluble polymer-drug conjugate is useful for
improving drug delivery to tumors.
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2.6 Figures

Figure 2.1. Maximal Tolerated Dose Evaluation of PolyMPC and PolyMPC-Dox A)PolyMPC
MTD-Weight change over time of NOD-SCID mice treated with intravenous administration of
polyMPC scaffold, doses ranging from 50-800mg/kg polyMPC. B)Intraperitoneal PolyMPCDox MTD-Weight change of NOD-SCID mice treated with intraperitoneal administration of
polyMPC Dox, ranging from 10-50mg/kg polyMPC-Dox, over time. C)Intravenous PolyMPCDox MTD-Weight change of NOD-SCID mice treated with intravenous administration of
polyMPC-Dox, ranging from 10-50mg/kg polyMPC-Dox, over time. D) Representative H&E
staining of liver sections of mice administered (A) HBSS, (B) 800 mg/kg polyMPC, and (C)
polyMPC-Dox at a 10 mg/kg Dox equivalent dose. All error Bars indicate +/- SEM, arrows
represent days of polymer or polyMPC-Dox administration. Images were taken at 20X
magnification with 40X magnification inlay images. All scale bars represent 50 µm.
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Figure 2.2 Biodistribution Analysis of PolyMPC-Dox. Biodistribution results following a
single injection of free Dox (6 mg/kg) or polyMPC-DOX (6 mg/kg Dox equivalent) in SKOV-3
tumor-bearing mice. Accumulation, expressed as ng Dox/g of tissue, was measured in tumors
and major organs using HPLC. Error bars represent ± the SEM.
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Figure 2.3 Evaluation of Efficacy of PolyMPC-Dox in Human Ovarian Tumor Model In
Vivo. Efficacy results for SKOV-3 tumor-bearing mice treated with HBSS (control), free Dox (2
mg/kg), polyMPC-Dox (5 mg/kg Dox equivalent dose) or doxil (5mg/kg) A) Survival curve B)
Average survival days C) Percent change in mean mouse weights D) percent change in mean
tumor volumes. Black=HBSS, Red=Free Dox, Blue=PolyMPC-Dox, Green=Doxil. Error bars
represent ± SEM, *=p<0.05.
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Figure 2.4 Evaluation of the In Vivo Cardiac Effects of PolyMPC-Dox Treatment A)
Proportional heart weights at time of euthenasia for NOD SCID mice, bearing subcutaneous
SKOV-3 human ovarian tumors, treated with multiple administrations of HBSS, Dox (2 mg/
kg), or polyMPC-Dox (5 mg/kg Dox equivalent dose) and doxil (5mg/kg). B)Representative
H&E staining of cardiac sections of mice administered HBSS, Dox (2 mg/kg), polyMPC-Dox
(5 mg/kg Dox equivalent dose) or doxil (5mg/kg) in a SKOV-3 human ovarian tumor efficacy
study. Error bars represent ± SEM. ****=p<0.0001. Images were taken at 20X magnification
with 40X magnification inlay images. Scale bars represent 50 µm.
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Figure 2.5 Evaluation of the In Vivo Pulmonary Effects of PolyMPC-Dox Treatment A)
Proportional lung weights at time of euthanasia for NOD SCID mice, bearing subcutaneous
SKOV-3 human ovarian tumors, treated with multiple administrations of HBSS, Dox (2 mg/
kg), or polyMPC-Dox (5 mg/kg Dox equivalent dose) and doxil (5mg/kg). B)Representative
H&E staining of lung sections of mice administered HBSS, Dox (2 mg/kg), polyMPC-Dox (5
mg/kg Dox equivalent dose) or doxil (5mg/kg) in a SKOV-3 human ovarian tumor efficacy study.
Red circles represent foamy cells likely indicative of lymphocytes within the lung. Error bars
represent ± SEM. ****=p<0.0001. Images were taken at 20X magnification with 40X
magnification inlay images. Scale bars represent 50 µm.
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Figure 2.6 Evaluation of the In Vivo Liver Effects of PolyMPC-Dox Treatment A)
Proportional liver weights at time of euthanasia for NOD SCID mice, bearing subcutaneous
SKOV-3 human ovarian tumors, treated with multiple administrations of HBSS, Dox (2 mg/
kg), or polyMPC-Dox (5 mg/kg Dox equivalent dose) and doxil (5mg/kg). B)Representative
H&E staining of liver sections of mice administered HBSS, Dox (2 mg/kg), polyMPC-Dox (5
mg/kg Dox equivalent dose) or doxil (5mg/kg) in a SKOV-3 human ovarian tumor efficacy study.
Error bars represent ± SEM. *=p<0.05. Images were taken at 20X magnification with 40X
magnification inlay images. Scale bars represent 50 µm.
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CHAPTER 3
TARGETED CHEMOTHERAPY UTILIZING MESENCHYMAL STEM CELLS
LOADED WITH POLYMPC

This research was performed in close collaboration with Nicholas Panzarino.

3.1 Introduction
Limitations associated with conventional systemic administration of
chemotherapeutics include off target drug effects that damage healthy tissue, thus
constraining therapeutic agents to a narrow window and diminishing their efficacy. The
therapeutic effect of cancer drugs is, in many cases, improved by their conversion to prodrugs [1]. In principle, prodrugs transport the therapeutic agent in a nontoxic form
through the bloodstream, thereby shielding the body from off target toxic effects and
improving the therapeutic profile of the drug [2,3]. In addition, polymer prodrugs also
improve drug delivery by passive tumor targeting via the enhanced permeability and
retention (EPR) effect, in which the fenestrated tumor vasculature preferentially traps and
retains the polymer prodrugs within the tumor [4-6]. After reaching the tumor, the drug is
released from the polymer by a variety of tunable mechanisms, such as hydrolysis and
enzyme driven chemistry [7].
Numerous examples of polymer pro-drugs exhibit improved pharmacokinetic and
biodistribution profiles [1]. Nevertheless, challenges remain for passively targeted agents
to overcome the physical defenses of solid tumors, including elevated interstitial and
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hydrostatic tumor pressure [8-11]. These elevated pressures arise from irregular tumor
vasculature [12], a disabled tumor lymphatic system [13], and the density of tightly
packed cancer cells [14], collectively impairing drug penetration. Furthermore, the
elevated pressures also impair uniform drug diffusion throughout the tumor, consequently
exposing tumor regions to ineffective drug concentrations and limiting their therapeutic
effect [15]. This represents a principle barrier to the efficacy of passively administered
agents, and may also facilitate the development of drug resistance in solid tumors [13].
MSCs are a pluripotent progenitor cell type which are most abundant in bone
marrow and adipose tissue. MSCs differentiate into adipocytes, chondrocytes, and
osteoblasts, and have been observed to migrate to sites of injury and to promote wound
healing. MSC specific migration holds potential for the treatment of damaged tissues
resulting from myocardial infarction and stroke, as well as for delivering secreted
therapeutic proteins to wounds [16].
MSCs have been reported to actively migrate to solid tumors and therefore hold
potential to actively transport therapeutic agents directly to tumors in order to overcome
their physical tumor defenses [17]. Use of MSCs in cancer therapeutics may ultimately
improve drug targeting, increase drug penetration, and reduce off target toxicities. Such
an approach has been evaluated previously as MSCs transduced to produce interferon β
reduced tumor growth in melanoma bearing mice [15].

Subsequent studies have

delivered a wider range of biologics or nanoparticles as a strategy to transport
chemotherapeutics agents to tumors utilizing MSCs [18-25]. For example, Zhang et al.,
loaded MSCs with doxorubicin (Dox) polymer conjugates which were intracranially
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injected into mice with glioma xenografts. Mice treated with MSCs carrying Dox
polymer conjugates experienced prolonged survival compared to control animals [25].
However, the therapeutic potential of drug loaded MSCs administered systemically has
yet to be evaluated.

3.2 Materials and Methods
3.2.1 Cell culture.
Human bone marrow mesenchymal stem cells (Cell Engineering Technologies,
(CET), Coralville, IA) were cultured in CET Mesenchymal Stem Cell Expansion
Medium (CET, Coralville, IA) without phenol red. MDA MB-231 breast cancer cells and
DO11.10 T-cells were grown in Dulbecco’s Modified Eagle Medium (DMEM, Thermo
Fisher, Grand Island, NY). All media was supplemented with 10% fetal bovine serum,
100U/mL penicillin and 100µg/mL streptomycin (Thermo Fisher, Grand Island, NY) and
cells were grown at 37°C and 5% CO2.

3.2.2 Polymer loading into MSCs.
Polymer loading was carried out with 1x106 cells per mL in Live Cell Imaging
Solution Physiological Buffered Saline (LCIS, Thermo fisher, Grand Island, NY)
suspension containing 10µM polymer solution of polyMPC-Rhodamine B (RhdB), 10µM
doxorubicin (Dox) equivilant polyMPC-Dox or 10µM free Dox at 37°C for 15 minutes.
Cells were centrifuged at 200 x g for five minutes at 37°C and the pellet was washed with
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LCIS to remove unbound polymer. Polymer uptake was confirmed with confocal
microscopy.

3.2.3 Cell viability.
Cell viability was evaluated using trypan blue exclusion performed on a Beckman
Coulter Vi-Cell Cell Viability Counter (Beckman Coulter, Brea, Ca). Viability was
determined after polymer loading on MSCs with either polyMPC-RhdB or polyMPCDox daily for up to 72 hours following polymer loading. Qualitative cell viability was
evaluated for up to 96 hours following polymer loading by transmitted light differential
interference contrast images utilizing live cell confocal microscopy.

3.2.4 Co-culture Experiment.
Drug release from MSCs was evaluated utilizing T-cell viability as a marker for
Dox release as T-cell viability is exquisitely sensitive to the presence of Dox. T-cells were
cultured with MSCs loaded with Dox or polyMPC-Dox. The viability of T-cells was
evaluated over 72 hours utilizing trypan blue exclusion with a Beckman Coulter Vi-cell
Viability Counter.

3.2.5 Evaluation of PolyMPC loaded MSC in vivo migration.
Non-obese diabetic severe combined immunodeficient (NOD SCID) mice were
implanted with 1X107 MDA MB-231 breast cancer cells in the right lateral flank. When
tumor volumes (calculated by tumor length X tumor width2)/2) grew to a minimum of
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500 mm3, mice were administered HBSS or 100,000-500,000 MSCs loaded with
polyMPC-RhdB provided via lateral tail vein injection. Five days following injection, the
mice were euthanized. Tumors were divided and sections were either flash frozen in
liquid nitrogen or formalin fixed and subsequently paraffin embedded.

3.2.6 Evaluation of polymer loaded MSC migration to tumor.
Frozen tumor sections embedded in optimal cutting temperature (OTC)
compound were cut at 4 µm thickness. Tumor sections were first imaged for RhdB
fluorescence to detect for the presence of polyMPC-RhdB loaded MSCs. Images for
polyMPC-RhdB were captured with a Nikon Eclipse Ti microscope equipped with an
Xcite Mercury Arc lamp and a Texas Red HyQ filter set (Nikon).
Immunohistochemistry (IHC) was performed on a Dako Cytomation autostainer
using the Envision HRP Detection system (Dako, Carpinteria, CA) following paraffin
embedding of formalin fixed tumor samples to evaluate for human CD105 (Ab169545,
Abcam, Cambridge, MA), specific to human bone marrow MSCs. Each mammary tissue
block was sectioned at 4µm on a graded slide, deparaffinized in xylene, rehydrated in
graded ethanols, and rinsed in Tris-phosphate-buffered saline (TBS). Heat induced
antigen retrieval was performed in a microwave at 98ºC in 0.01M citrate buffer. After
cooling for 20 minutes, sections were rinsed in TBS and subjected to an antibody specific
for human CD105 at 1:400 dilution for 45 minutes. Immunoreactivity was visualized by
incubation with chromogen diaminobenzidine (DAB) for 5 minutes. Tissue sections were
counterstained with hematoxylin, dehydrated through graded ethanols and xylene, and
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cover-slipped. Images were captured with an Olympus BX41 light microscope using
SPOT™Imaging Solutions (Detroit, MI).

3.2.7 Statistical Analysis
All graphs were created and statistical analysis was performed utilizing GraphPad
Prism Software (Prism, GraphPad Software, Inc., San Diego, CA).

3.3 Results
3.3.1 PolyMPC-RhdB and PolyMPC-Dox Polymers are Stably Loaded onto MSCs.
Following incubation of MSCs with polyMPC-RhdB, no reduction in viability was
observed up to 72 hours following treatment (Fig 3.1C). Further, no reduction in viability
was observed upon loading of MSCs with polyMPC-Dox as well (Fig 3.1D). Confocal
microscopy revealed a distinctive filamentous pattern of cytoplasmic fluorescence with
sparing in the nucleus observed in both polyMPC-RhdB and polyMPC-Dox (Fig 3.1B)
loaded MSCs. This pattern of florescence was observed to be stable for up to 96 hours. In
contrast, MSCs loaded with Dox exhibited a diffuse pattern of fluorescence (Fig. 3.1A)

3.3.2 MSC Co-Culture Experiment
Drug release from MSCs was evaluated utilizing T-cell viability as a marker for
Dox release, given exquisite T-cell sensitivity to Dox. Co-culture of T-cells with MSCs
loaded with Dox led to a reduction in T-cell viability over 72 hours (Fig 3.2A). In
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contrast, MSCs loaded with polyMPC-Dox did not lead to appreciable T-cell death (Fig
3.2B).

3.3.3 PolyMPC-RhdB Loaded MSCs Home to Tumors In Vivo.
Mice with established subcutaneous human mammary tumor (MBA MB-231)
xenografts were treated with polyMPC-RhdB loaded MSCs. Five days after the MSCs
were administered, mice were euthanized, necropsy was performed and tumors were
evaluated in order to determine if MSCs had transported their polymer cargo to the solid
tumors. Frozen tumor sections imaged for RhdB fluorescence to detect for the presence
of MSCs containing polyMPC-RhdB revealed distinct fluorescent foci present throughout
the tumor sections. In contrast, tumors from mice treated with saline were not fluorescent
(Fig 3.3). Immunohistochemistry (IHC) was performed on paraffin-embedded tumor
sections using a human CD105 antibody specific for human MSCs. We observed antiCD105 antibody to stain tumor sections from mice treated with polyMPC-RhdB loaded
MSCs while negligible staining was observed in the saline control tumors (Fig. 3.3).

3.4 Discussion
While a wide variety of treatment options are available for the treatment of
cancer, therapy is often limited by the toxicities associated with these chemotherapeutic
agents. Means to improve drug targeting directly to tumors can result in increased uptake
of the drugs into the tumor as well as reduced uptake in other off target organs.
Conjugation of these drugs to polymers, such as polyMPC, can allow for passive
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targeting of the tumor through the enhanced permeability and retention (EPR) effect [26,
27]. Delivery of these prodrugs can be further improved through utilization of a more
active and targeted method.

Here, we evaluated a cellular tumoritropic vehicle for

polymer drug delivery through utilization of MSCs.
MSCs were able to stably uptake both polyMPC-RhdB and polyMPC-Dox. For
this work, Rhodamine B (RhdB) bound to polyMPC was utilized in addition to
polyMPC-Dox because RhdB’s brighter fluorescence allowed for a facile analysis of
cellular uptake. Following incubation of MSCs with polyMPC-RhdB, no reduction in
viability was observed for up to 72 hours following treatment. Repeat analysis utilizing
polyMPC-Dox also revealed stable uptake. Confocal microscopy confirmed uptake of
both polymers without altering viability for upto 96 hours. Compared to free Dox, both
polyMPC-RhdB and polyMPC-Dox exhibited a filamentous pattern of fluorescence
throughout the cytoplasm consistent with intracellular localization within the
mitochondria. In constrast, free Dox uptake within MSCs was noted to be diffuse
throughout both the cytoplasm and nucleus.
Drug release from MSCs was evaluated utilizing T-cell viability as a marker for
Dox release, given exquisite T-cell sensitivity to Dox. Co-culture of T-cells, a
suspensatory cell line, with MSCs, an adherent cell line, which were loaded with Dox led
to a reduction in T-cell viability over 72 hours. This provided evidence that MSCs can not
only be loaded with Dox, but can also release the drug. In contrast, MSCs loaded with
polyMPC-DOX did not lead to appreciable T-cell death. It remains unclear this difference
in outcome is secondary to reduced drug uptake or reduced drug release by the MSCs.
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Following the observation that MSCs can be stably loaded with polyMPC- Dox
and have the potential for drug release in vitro, the in vivo migratory capabilities of
polymer loaded MSCs was evaluated. We observed that MSCs containing their polymer
cargo maintained their tumoritropic abilities. MSC lmigration was evaluated both with
fluorescent microscopy to evaluate for the presence of polyMPC-RhdB as well as through
IHC to assess for human cd105, which is specific for MSCs. Together, fluorescent
imaging and IHC confirmed that systemically administered MSCs actively transport to a
solid tumor while loaded with polymer cargo. This suggests that MSCs can serve as
vehicles for actively targeted delivery of drugs, including polyMPC prodrugs.

3.5 Conclusion
In summary, cellular vehicles with inherent tumoritropic properties, such as
MSCs, provide the unique ability to actively target and deliver chemotherapeutic drugs to
tumors. This potentially allows for improved efficacy and reduced off target toxicity. We
found that polyMPC can be stably loaded into MSCs and that the cells maintain their
tumoritropic capabilities and can migrate to established tumor xenograft upon systemic
administration in vivo. This work provides evidence that MSCs hold potential to improve
active tumoral drug delivery of polymer prodrugs and future work will focus on drug
release and therapeutic efficacy of drug loaded MSCs.
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3.6 Figures

Figure 3.1 MSC Drug Uptake and Viability. A) Live cell confocal microscopic image (63X) of
MSCs loaded with Dox B) Live cell confocal microscopic image (63X) of MSCs loaded with
PolyMPC-Dox. C)Viability of polyMPC-RhdB loaded MSCs evaluated by trypan blue exclusion.
Red=polyMPC-RhdB MSCs, Black=untreated MSCs. D) Viability of polyMPC-Dox loaded
MSCs evaluated by trypan blue exclusion. Green=polyMPC-Dox MSCs, Black=untreated MSCs.
Error bars represent standard deviation.
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Figure 3.2 MSC Co-culture Experiment. A) 72 hour viability analysis, evaluated by trypan blue
exclusion, of T-cells (DO11.10) grown in either MSC conditioned media (red), 1uM FD (dark
blue), co-culture with MSC loaded DOX (blue) or with DOX loaded MSC conditioned media
(light blue). B) 72 hour viability analysis, evaluated by trypan blue exclusion, of T-cells grown in
either MSC conditioned media (red), 1uM DOX equivalent polyMPC DOX (dark green), coculture with MSC loaded with polyMPC-DOX (green) or with polyMPC-loaded MSC
conditioned media (light green).
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Figure 3.3 Polymer Loaded MSC Tumor Homing In Vivo A) Left: Fluorescent microscopic
images (10X) of RhdB fluorescence from a frozen tumor section from a mouse treated with
polyMPC-RhdB loaded MSCs. Right: Microscopic images (20X) of a paraffin embedded tumor
section from a mouse treated with polyMPC-RhdB loaded MSCs immunohistochemically stained
with human CD105. B) Fluorescent microscopic images (10X) of RhdB fluorescence from a
frozen tumor section from a mouse treated with saline. Right: Microscopic images (20X) of a
paraffin embedded tumor section from a mouse treated with saline immunohistochemically
stained for human CD105. Scale bars for all images represent 50uM
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CHAPTER 4
EVALUATION OF RHODIOLA CRENULATA ON THE TREATMENT OF
MELANOMA

This research was performed in close collaboration with Maxine Dudek and Dr. Carmen
Mora.

4.1 Introduction
Each year, more than 76,000 people in the United States are diagnosed with
melanoma, the most aggressive form of skin cancer [1]. Melanoma arises from the
malignant transformation of melanocytes. Melanocytes specialize in melanogenesis or the
production of melanin, a pigment that protects the skin by absorbing and scattering
harmful solar radiation [2]. During the development of melanoma, mutated melanocytes
display rapid proliferation and growth. Melanomas that grow laterally or display a radial
growth phase (RGP) pattern are typically less aggressive than those displaying a vertical
growth phase (VGP) pattern [3]. At present, primary cutaneous melanomas are staged
according to their thickness or vertical growth. With increasing T stage category,
cancerous cells are more likely to invade into through the basement membrane resulting
in an increased risk of metastatic spread [4-6]. Given its aggressive behavior the five year
survival rate for patients diagnosed with metastatic melanoma is less than 16% [1].
At present, early detection of melanoma is the most important means to improve
disease survival. Primary treatment involves surgical resection, brachytherapy, targeted
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molecular therapy, and/or immunotherapy. Despite these aggressive interventions,
treatment options for patients with metastatic disease remain limited and typically is
associated with a poor prognosis. Consequently, investigations into novel treatment
options are necessary for patients with this aggressive disease. One promising treatment
option is the extract derived from Rhodiola crenulata (RC) plant roots. RC is a small
perennial plant cultivated in barren soils and high altitudes in the tundra regions of
Siberia and the highlands of Tibet. Traditionally, the phenolic phytochemicals extracted
from the root of RC have been used to treat disorders such as depression, anxiety, and
fatigue [7-10]. Recent studies have demonstrated the therapeutic potential of RC in a
variety of malignancies including bladder cancer, breast cancer, and glioblastoma
[11-14]. Given the anti-tumorigenic properties observed with the use of Rhodiola plant
extracts both in vitro and in vivo, this current study was designed to evaluate the
therapeutic potential of RC root extract on a melanoma cell line.

4.2. Materials and Methods
4.2.1 R. crenulata Preparation.
RC root extract was obtained in powdered form from Barrington Chemical
Corporation (Harrison, NY). For cell culture and oral administration experiments, RC
powder was dissolved in a 10% ethanol solution in distilled water and was filter
sterilized. Cream-based RC for topical experiments was prepared by the addition of 5%
or 10 % RC by weight to a 10% DMSO-Eucerin™-based cream.
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4.2.2 Cell Culture.
B16-F10 (CRL-6475™) murine melanoma cell culture line was obtained from
ATCC® (Manassas, VA). Cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/
mL streptomycin (Thermo Fisher, Grand Island, NY) at 37°C under 5% CO2.

4.2.3 Evaluation of viability and proliferation.
A CellTiter96® Aqueous One Solution MTS Assay (Promega, Madison, WI)
assay was performed according to the manufacturer’s directions in order to test for cell
growth and proliferation. A total of 5X103 B16-F10 cells were seeded on a 96-well
microtiter plate and treated with 200 µg/mL RC or ethanol vehicle control and assay was
performed in quintuplicate. After incubation for 24, 48, and 72 hours following treatment,
the plate was spun at 2000 X g for one minute, treated media was decanted and replaced
with 100µL of 1X PBS with 20 µL of MTS reagent per well. The plate was then
incubated at 37°C in a humidified, 5% CO2 atmosphere for three hours. The absorbance
of each well was recorded at 490 nm using an Enspire® multimode automated plate
reader (PerkinElmer, Waltham, MA).

4.2.4 Clonogenecity assay.
A total of 200 B16-F10 cells were seeded onto 60-mm tissue culture plates. After
allowing the cells to adhere for 24 hours, plates were treated with 100 µg/mL RC or
vehicle control for 1 hour +/- exposure to 5 Gy radiation or sham treatment. The media
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was replaced with appropriate treatment every four days. On day 11, colonies were fixed
in methanol and stained with 2% crystal violet in a 50% methanol solution. Colonies
were defined as a cluster of five or more cells. The number of colonies were quantified
visually and compared between treatment groups. The experiment was performed in
triplicate.

4.2.5 Migration assay
Migration and cell growth were evaluated using a scratch wound assay. B16-F10
cells were plated on 30-mm dishes and allowed to reach 100% confluency and then a
scratch was made down the center of each culture with a pipette tip. Plates were then
treated with 100 µg/mL RC or ethanol vehicle control, and cell growth was monitored
over 48 hours. Images of the plates were captured daily with Nikon Eclipse TE2000-U
using Metaview™ software (Universal Imaging Corporation).

4.2.6 Evaluation of Topical RC Therapy on a Subcutaneous Melanoma In Vivo.
Thirty 8-week-old virgin C57BL/6 female mice were housed in plastic cages and
were permitted free access to food and water. A total of 1X106 B16-F10 cells were
implanted subcutaneously above the scapular fat pad. Daily topical RC treatment was
initiated 24 hours following tumor implantation. Treatment groups (10 animals/group)
included the following: 5% RC cream, 10% RC cream, and DMSO control cream. Mice
were evaluated daily, and tumor volume measurements were obtained once tumors
became palpable. Tumor volume was calculated by (tumor length X tumor width2)/2, in
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which the tumor width was the smaller of the two measured values. Mice were
euthanized if they appeared to be in any distress, exhibited greater than 15% weight loss,
or when tumor volume exceeded 1500 mm3. Upon euthanasia, necropsy was performed,
and tissues were preserved in 10% formalin. Excised tumors were paraffin embedded and
stained with hematoxylin and eosin (H&E, Poly Scientific, Bay Shore, NY). The total
number of mitotic cells was quantified in three representative images at 40X power per
tumor sample obtained from each mouse in the DMSO and 10% RC treated groups.
Images were captured with an Olympus BX41 light microscope using SPOTSOFTWARE
(Diagnostic Instruments, Inc.).

4.2.7 Evaluation of Enteral RC Therapy on a Subcutaneous Melanoma In Vivo.
Subcutaneous B16-F10 tumors were established overlying the scapula of 20
C57BL/6 mice. Beginning 24 hours prior to tumor implantation, drinking water of ten
mice per treatment group was supplemented with either 50mg/kg RC or ethanol vehicle
control. Mice were evaluated daily, and tumor volume measurements were obtained once
tumors became palpable. Tumor volume was calculated by (tumor length X tumor
width2)/2, in which the tumor width was the smaller of the two measured values. Mice
were euthanized if greater then 15% weight loss was observed, tumor volume exceeded
1500mm3 or mice exhibited any signs of distress. Necropsy was performed at time of
euthanasia. Outcomes, including length of survival and tumor growth were compared
between treatment groups.
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4.2.8 Evaluation of RC to Prevent the Establishment of Metastatic Melanoma In Vivo
Sixteen 8-week-old C57BL/6 female mice were pretreated for three days with
100mg/kg RC or vehicle supplemented water (8 mice/group). A total of 1X105 B16-F10
cells were injected via lateral tail vein to model a disseminated disease state. Mice were
evaluated daily, and water was replaced with appropriate treatment every 48 hours. Mice
were euthanized if they appeared to be in any distress or exhibited more than 15% weight
loss. All surviving mice were euthanized 30 days following tumor injection. At the time
of euthanasia, the lungs were preserved in Fekete’s solution [15], while remaining organs
were preserved in 10% formalin. The lungs were evaluated for gross establishment of
metastatic foci, and photos were obtained of gross lung specimens. Formalin-fixed
paraffin-embedded lungs were further analyzed histologically by H&E staining.
Representative images of H&E-stained lung sections were taken using an Olympus BX41
light microscope using SPOTSOFTWARE (Diagnostic Instruments, Inc.).

4.2.9 Statistical analysis
All results were analyzed using either a two-tailed student’s t-test with one-way
analysis of variance (ANOVA) or a two-ANOVA with a Bonferroni’s correction.
Statistical outliers were identified utilizing a rout test [16]. All graphs were created and
statistical analysis was performed using GraphPad Prism Software (Prism, GraphPad
Software, Inc., San Diego, CA).

4.3. Results
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4.3.1 RC induces morphological changes in B16-F10 cells.
B16-F10 cells are typically adherent, flat, and have multiple dendritic projections.
Upon treatment of these cells with increasing doses of RC, we observed phenotypic
changes at doses greater than 200 µg/mL RC. Cells treated with RC exhibited reduced
dendritic projections, became rounder, and were less adherent (Fig 4.1A).

4.3.2 RC decreases B16-F10 proliferation
To assess RC’s effect on growth and proliferation, we performed an MTS assay on
B16-F10 cells treated with either RC (200 ug/mL) or vehicle control. Following 24 hours
of treatment an initial trend toward decreased proliferation was observed in RC treated
cells. By 48 and 72 hours, a significant reduction in proliferation was observed upon RC
treatment (p<.01 and p<.0001, respectively, Fig. 4.1B).

4.3.3 RC Decreases Colony Formation of B16-F10 Cells
To evaluate RC treatment efficacy, a clonogenecity assay was performed. RC
treatment significantly reduced the number of colonies established (p<.001) compared to
vehicle control (Fig. 4.1C). However, radiation sensitivity did not appear to be enhanced
by treatment with RC.

4.3.4 RC Decreases Cellular Migration of B16-F10 Cells
To determine if RC affects migration of B16-F10 cells, a scratch wound assay was
performed. Cultures treated with vehicle control exhibited complete wound closure by 48
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hours, while cells treated with RC maintained distinct wound boundaries with minimal
growth at 48 hours (Fig 4.1D).

4.3.4 Evaluation of the Topical RC treatment on subcutaneous B16-F10 Tumors In Vivo
A trend toward increased survival was observed in mice treated with RC. Mice
treated with 5% RC and 10% RC met requirements for euthanasia by days 15 and 20,
respectively, while mice treated with vehicle met requirements for euthanasia by 14 days
(Fig 4.2A). Further, one mouse treated topically with 5% RC exhibited complete
regression of the subcutaneous tumor and survived for over 30 days. There was no
difference in the final weights of mice at the time of euthanasia (Fig 4.2C). While no
significant difference was observed in the overall size of the measured tumor volume (Fig
4.2B, D), tumors in mice treated with vehicle control tended to be raised, while animals
treated with RC displayed a more horizontal growth pattern (Fig 4.3A).

Additionally,

tumors treated with RC exhibited a significantly lower number of active mitotic figures
per high power field compared to the vehicle-treated mice (Fig 4.3C, D, p=.0374).

4.3.5 Evaluation of the Enteral RC treatment on subcutaneous B16-F10 Tumors In Vivo
Similar to the topical RC experiments, there was no signficant difference
observed in the survival and tumor growth in mice treated with RC enterally compared to
vehicle control (Fig 4.4A). At the time of euthanasia, there was no difference in the
weight of the mice, tumor volume or tumor weight (Fig 4.4 B, C, D respectively).
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Additionally, there were no gross difference in tumor growth patterns observed amongst
treatment groups.

4.3.6 Evaluation of Enteral RC to Prevent Establishment of Metastatic Melanoma
Upon necropsy performed 30 days following tumor injection, a striking difference
in the tumor establishment within the lungs was observed. Mice treated with RC
exhibited a reduction in tumor burden established in the lungs compared to mice treated
with ethanol vehicle control (Fig 4.5A). No other organs bore a similar difference in
tumor establishment. Total lung weights confirmed our gross findings, in which there was
a significant decrease in the weight of lungs treated with RC compared to vehicle control
(Fig 4.5B, p<0.05). Additionally, histologic examination of the lungs confirmed reduced
establishment of tumor foci in animals treated with RC.

4.4 Discussion
Melanoma is the most aggressive and deadliest form of skin cancer. The SEER
database estimated that melanoma was responsible for the death of more than 9,000
Americans in 2015 [1]. Currently, prevention and early detection are the best methods to
reduce the mortality rate associated with melanoma. Unfortunately, effective treatment
options for cases of advanced and disseminated disease remain limited. Consequently,
there may be significant value in identifying natural products that possess potent
anticancer properties. Rhodiola plant extracts have exhibited a number of antitumorigenic properties in a variety of cancers and have been shown to promote cell death
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and inhibit both proliferation and angiogenesis within a variety of cancers [11,12,14,17].
Based on the data presented above, RC extract, and the compounds contained within it,
may represent a potentially novel and effective melanoma therapy.
In this study, we evaluated the effect of RC on an aggressive melanoma cell line,
B16-F10. Upon treatment with RC in vitro, B16-F10 cells exhibited morphological
changes, reduced proliferation, increased cell death, and reduced colony formation
compared to vehicle controls. Given the promising effects observed with RC treatment
upon melanoma cells in vitro, investigation of the therapeutic effects of this extract were
then evaluated in vivo.
While no overt difference in the survival and tumor growth in mice with
subcutaneous tumors treated with RC were observed, differences in growth patterns and
mitotic activity was observed in tumors treated with topical RC. Upon topical RC
treatment, tumors displayed more horizontal growth patterns while the tumors of vehicle
control treated mice tended to grow more vertically. Of note, the endpoint for the
investigation of RC treatment of subcutaneous tumors was based on the length and width
of the pigmented area, but not on the vertical axis in tumor volume measurements. If the
vertical axis had been a consideration, then the overall survival time of RC-treated
animals compared to vehicle control-treated animals may have resulted in a significant
improvement in survival. The differences in growth patterns observed is critical as
melanoma displaying radial growth patterns are associated with considerably lower rates
of metastatic disease compared to the more aggressive and vertically growing
phenotypes.
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Upon further histologic analysis of tumor sections, topical RC treated tumors
displayed reduced mitotic activity. High mitotic rates in cutaneous melanomas are known
to be associated with more aggressive disease phenotypes and significantly lower
survival rates [19-23]. Therapeutic agents that reduce the mitotic rates of melanomas
have the potential to reduce tumor growth and improve overall survival. This further
suggests that RC can reduce the aggressive potential of melanoma tumors in vivo.
Topical application of RC creams resulted in phenotypic changes in the tumor that
are associated with less aggressive behavior. While RC has previously been used
topically to reduce the size of pigmented lesions [24], this work is the first to suggest that
the RC is bioactive when applied topically in the setting of a cutaneous neoplasm. In
contrast, enterally administered RC did not result in any changes in tumor growth or
histologic characteristics. While RC has previously been shown to be bioavailable upon
enteral administration in the setting of other cancers, there are several reasons as to why
RC administered topically was more effective then enterally administered RC in this
study. First, RC doses provided enterally may may have lead to poor tumor uptake while
topically administered RC may have lead to more concentrated uptake within the tumor
bed directly. Additionally, B16-F10 melanoma is a syngeneic line with C57BL/6 mice,
resulting in very aggressive growth and dissemination following tumor implantation. As
such, tumor growth may have exceeded the ability to observe any efficacious changes
following RC treatment administered enterally.
Upon in vivo evaluation of RC treatment in a disseminated model of melanoma, a
dramatic reduction in the establishment of metastatic foci in the lungs was observed.
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Given this, RC’s ability to prevent establishment of metastatic disease is very promising
as a novel therapy for melanoma. The molecular detection of circulating tumor cells in
patients with melanoma has been established as a negative prognostic indicator,
emphasizing the impact of hematogenous spread on overall survival [25, 26]. Current
treatments for locally or regionally advanced disease, such as interferon, provide only
minimal improvements in patient survival. Treatments that may further prevent the
development of metastatic lesions, such as RC, can potentially be utilized as an adjunct to
other chemotherapeutic agents to prevent further dissemination of the disease.

4.5 Conclusion
In summary, treatment of B16-F10 melanoma with RC resulted in promising antineoplastic properties noted both in vitro and in vivo. We observed that RC was cytotoxic
to melanoma cells and reduced cell proliferation and migration in vitro. We also observed
that topical RC could impede more aggressive vertical growth characteristics of tumors
critical for the establishment of metastatic disease. Furthermore, our findings demonstrate
the potential anti-metastatic activity of this extract when utilized in a disseminated model
of melanoma. The identification of novel agents with chemotherapeutic potential, such as
RC, is important for the improvement of overall patient survival. Thus, Rhodiola plant
extracts may have a place in the future as an adjuvant therapeutic agent for the treatment
of melanoma.

61

4.6 Figures

Figure 4.1 In Vitro Effects of RC treatment upon Melanoma A) Phase contrast image
representation of B16-F10 cells treated for 72 hours with 100 µg/mL R. crenulata or ethanol
vehicle. B) MTS assay performed on cells treated with Rhodiola or vehicle control evaluated at
24, 48 and 72 hours. C) Clonogenicity assay performed on cells treated with either Rhodiola on
vehicle control with or without exposure to 5 Gy radiation. All colonies containing more then five
cells that grew following 8 days of therapy were quanitified. D) Scratch wound healing assay
performed on a confluent monolayer of cells treated with either Rhodiola or vehicle control.
Scratch wound healing was observed at 15 minute, 4, 24 and 48 hour time intervals. All images
were obtained at 20X magnification. Error bars represent ± standard error of the mean. *=p<0.05,
***=p<0.001, ****=p<0.0001.
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Figure 4.2 Outcomes of Topical RC Treatment of Melanoma In Vivo. A) Survival Curve of
C57BL/6 mice with B16-F10 subcutaneous tumors treated with topical DMSO cream (red), 5%
RC (dark blue) and 10% RC (light blue). NS=non-signficant. B) Change in tumor growth over
time among treatment groups including DMSO cream (Dark blue), 5% RC cream (dark purple)
and 10% RC (light purple). C) Average mice weight at time of euthaniasia. D) Tumor weight (g)
at time of euthanasia. Error bars indicate ± standard error of the mean.
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Figure 4.3 Gross and Pathological Changes upon Topical RC Treatment of Melanoma. A)
Photographic representation of tumors treated topically with 5% or 10% R.crenulata cream or
vehicle cream. B) Image representation of histological tumor specimens stained with hematoxylin
and eosin. Red arrows indicate mitotic cells. Images were captured at 40X magnification. C)
Average number of mitotic cells present within each representative 40X field and compared
between mice treated with vehicle cream and 10% Rhodiola cream. Error bars represent ±
standard error of the mean, *p<0.05.
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Figure 4.4 Outcomes of Enteral RC Treatment of Melanoma In Vivo. A) Survival Curve of
C57BL/6 mice with B16-F10 subcutaneous tumors treated with enteral 50mg/kg RC or ethanol
vehicle control. B) Mouse weight (g) at time of euthanasia comparing ethanol treated (blue) to
RC treated (yellow). C) Tumor volume at time of euthanasia. D) % Total body weight of tumor
compared to total mouse weight at time of euthanasia. Error bars indicate ± standard error of the
mean.
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Figure 4.5 Effects of Enteral RC Treatment on the Establishment of Metastatic Melanoma
A) Photographic representation of lungs of C57BL/6 mice at 30 days following disseminated
B16-F10 tumor administration via lateral tail vein injection in mice treated with ethanol
supplemented water or 100mg/kg RC supplemented water B) Lung weight (g) at time of
euthanasia of mice treated with ethanol or 100mg/kg RC, ROUT Test was performed to identify
statistical outliers. Error bars indicate ± standard error of the mean, *=p<0.05.

66

4.7 References

1. Melanoma of the Skin. In: turning cancer data into discovery. surveillance,
epidemiology, and end results (SEER) program. 2004–2010. http://seer.cancer.gov/
statfacts/html/melan.html. Accessed 12 March 2015.
2. Tadokoro Tet al. UV-induced DNA damage and melanin content in human skin
differing in racial/ethnic origin. FASEB J. 2003. doi:10. 1096/fj.02-0865fje.
3. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of
cutaneous melanoma. Ann Surg. 1970;5:902–8.
4. Balch CM, Gershenwald JE, Soong S, et al. Staging and primary tumor mitotic rate. J
Surg Oncol. 2011;104:379–85.
5. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev
Cancer. 2003;3:559–70.
6. Bedrosian I, FariesMB, Guerry D, et al. Incidence of sentinel node metastasis in
patients with thin primary melanoma (#1 mm) with vertical growth phase. Ann Surg
Oncol. 2000;7:262–7.
7. Brown RP, Gerbarg PL. The rhodiola revolution. 1st ed. Holtzbrinck Publishers; 2004.
8. Darbinyan V, Aslanyan G, Amrovan E, et al. Clinical trial of Rhodiola rosea L. extract
SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry.
2007;61:343–8.
9. Dwyer AV,Whitten DL,Hawrelak JA.Herbalmedicines, other than St. John’sWort, in
the treatment of depression: a systematic review. J Clin Ther. 2001;16:40–9.
10.Pannossian A, Wilkman G, Sarris J. Rosenroot (Rhodiola rosea): traditional use,
chemical composition, pharmacology and clinicalefficacy. Phytomedicine.
2010;17:481–93.
11.Gauger KJ, Rodríguez-Cortés A, Hartwich M, et al. Rhodiola crenulata inhibits the
tumorigenic properties of invasive mammary epithelial cells with stem cell
characteristics. J Med Plants Res. 2010;4:446–54.
12.Tu Y, Roberts L, Schneider SS. Rhodiola crenulata induces death and inhibits growth
of breast cancer cell lines. J Med Food. 2008;11:413–23.

67

13.Liu Z, Li X, Simoneau AR, Jafari M, et al. Rhodiola rosea extracts and salidroside
decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway
and induction of autophagy. Mol Carcinog. 2012;51:257–67.
14.Mora MC, Bassa LM, Wong KE, et al. Rhodiola Crenulata inhibits Wnt/β-catenin
signaling in glioblastoma. J Surg Res. 2015;197(2): 247–55.
15.Overwijk WW, RestifoNP. B16 as a mouse model for human melanoma. Curr Protoc
Immunol. 2001. doi:10.1002/0471142735.im2001s39.
16.Motulsky HJ, Brown RE. Detecting outliers when fitting data with nonlinear
regression – a new method based on robust nonlinear regression and the false
discovery rate. BMC Bioinf. 2006. doi: 10.1186/1471-2105-7-123.
17.Skopińska-Różewska E, Hartwich M, Siwicki AK, et al. The influence of Rhodiola
rosea extracts and rosavin on cutaneous angiogeneis induced inmice after grafting of
syngeneic tumor cells. Cent Eur J Immunol. 2008;33:102–7.
18.Elder DE. Pathology of melanoma. Clin Cancer Res. 2006;12: 2309–11.
19. Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma
development and progression. Front Biosci. 1998;3: 1005–10.
20. Thompson JF, Soong S, Balch S, et al. Prognostic significance of mitotic rate in
localized primary cutaneous melanoma: an analysis of patients in the MultiInstitutional American Joint Committee on cancer melanoma staging database. J Clin
Oncol. 2011;29:2199– 205.
21. AzzolaMF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful
prognostic indicator than ulceration in patients with primary cutaneous melanoma.
Cancer. 2003;97:1488–98.
22. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma
staging and classification. J Clin Oncol. 2009;27: 6199–206.
23. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor
mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long
follow-up. Ann Surg Oncol. 2004;11:426–33.
24. ChiangH, Chien Y,Wu C, et al. Hydroalcoholic extract of Rhodiola rosea L.
(Crassulaceae) and its hydrolysate inhibit melanogenesis in B16F0 cells by regulating
the CREB/MITF/tyrosinase pathway. Food Chem Toxicol. 2014;65:129–39.

68

25. Mellado B, Gutierrez L, Castel T, et al. Prognostic significance of the detection of
circulating malignant cells by reverse transcriptase polymerase chain reaction in longterm clinically disease-free melanoma patients. Clin Cancer Res. 1999;5:1843–8.
26. Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic
indicators of melanoma recurrence. Cancer Res. 2000;60:2253–7.

69

CHAPTER 5
EVALUATION OF RHODIOLA CRENULATA ON THE TREATMENT OF
NEUROBLASTOMA

5.1 Introduction
Neuroblastoma is the most common extra-cranial solid malignancy in infants and
children. Occurring in approximately 1 in 100,000 children, neuroblastoma is responsible
for 15% of all pediatric cancer deaths [1-4]. While these tumors of neurocrest origin may
arise anywhere along the sympathetic ganglion chain, they most commonly arise from the
adrenal medulla[1].

The clinical course of this highly malignant neoplasm is quite

variable depending on the location of the primary tumor, age of the patient, and stage of
disease at presentation. The DNA content of cells, amplification status of the protooncogene MYCN, the stage of disease, and age of the patient at presentation are
important variables for determining the treatment and outcomes of this aggressive disease
[1]. Despite intensive research therapeutic options for these patients, outcomes of
children with aggressive variants of neuroblastoma continues to remains poor.
The treatment of neuroblastoma typically involves surgical resection and multiagent chemotherapy. The toxicity of chemotherapy required often limits therapy in this
young and fragile population. Children who receive chemotherapy at such of a young age
are susceptible to the life long effects of the morbidities associated with these drugs
including hepatotoxicity, nephrotoxicity or cardiotoxicity [5]. Further, children are at
increased risk for developing long term side effects of these agents, such as the
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development of myelodysplastic syndromes [5]. Any novel agent that can effectively treat
this disease or serve as an adjunct to reduce the toxicities associated with current
therapeutic options, offers the potential to limit or eliminate these devastating systemic
toxicities and improve therapeutic outcomes in children with neuroblastoma.
Given the anti-cancer properties that RC has displayed in a variety of cancers
[6-10], such as breast cancer [7-8], glioblastoma [9] and melanoma [10], this work sought
to evaluate the effects that RC extract has both in vitro and in vivo as a novel method for
the treatment of neuroblastoma.

5.2 Materials and Methods
5.2.1 RC Preparation
RC root extract was obtained in powdered form from Barrington Chemical
Corporation (Harrison, NY). For cell culture and oral administration experiments, RC
powder was dissolved in a 10% ethanol solution in distilled water and was filter
sterilized.

5.2.2 Cell Culture
Two human neuroblastoma cell lines were evaluated for this work which were
graciously provided by Dr. Andrew Davidoff’s labs of St. Jude’s Hospital for Children.
The first cell line, NB-1691, is a MYCN amplified neuroblastoma line derived from a
recurrent retroperitoneal tumor in a 1.9 year old male [11]. The second line evaluated is
SK-N-AS, which are non-MYCN amplified cells obtained from the bone marrow of an
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eight year old female with recurrent neuroblastoma [11]. Cells were cultured in either
Roswell Park Memorial Institute (RPMI)-1640 medium containing 2mM of glutamine
(Thermo Fisher, Grand Island, NY) or Dulbecco’s Modified Eagle’s Medium (DMEM,
Thermo Fisher, Grand Island, NY). All media was supplemented with 10% fetal bovine
serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco®, Grand Island,
NY) and all cells were cultured at 37°C under 5% CO2.

5.2.3 Evaluation of Viability with Trypan Blue Exclusion.
Cell viability was determined by trypan blue exclusion performed on a Beckman
Coulter Vi-Cell Cell Viability Counter (Beckman Coulter, Brea, Ca).

5.2.4 MTS Proliferation Assay
A CellTiter96® Aqueous One Solution MTS (Promega, Madison, WI) assay was
performed according to the manufacturer’s directions in order to test for cell growth and
proliferation. A total of 1X104 cells were seeded on a 96-well microtiter plate and treated
with 0-200 µg/mL RC or ethanol vehicle control. After incubation for up to 96 hours,
media was removed and replaced with 100µL of 1X PBS mixed with 20 µL of MTS
reagent per well. The plate was then incubated at 37°C until color development occurred
(between 1-4 hours). The absorbance of each well was evaluated at a wavelength of 490
nm using an Enspire® multimode automated plate reader (Perkin Elmer, Waltham, MA).

5.2.5 Clonogenecity assay.
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A total of 300 NB-1691 cells were seeded onto 60-mm tissue culture dishes in
which three plates were evaluated per treatment group. After allowing the cells to adhere
for 24 hours, plates were then treated with 50 µg/mL RC or vehicle control. Plates were
also additionally treated with +/- exposure to 5 Gy radiation one hour following RC
treatment. The media was replaced with the appropriate treatment every 3-4 days. Once
colonies were grown and established (approximately two weeks), cells were then fixed in
methanol and stained with 2% crystal violet in a 50% methanol solution. Colonies were
defined as a cluster of five or more cells. The number of colonies were quantified visually
and compared between treatment groups. The experiment was performed in triplicate.

5.2.6 Scratch Wound Migration Assay
NB-1691 and SK-N-AS cells were plated on 30-mm dishes and allowed to reach
100% confluency. Following this, a scratch was made down the center of each culture
dish using a pipette tip. Plates were then treated with 100 µg/mL RC or ethanol vehicle
control. Cell growth was monitored over 72 hours. Images of the plates were captured
daily with Nikon Eclipse TE2000-U using Metaview™ software (Universal Imaging
Corporation).

5.2.7 Transwell Migration Assay
NB-1691 cells were pretreated with 100 µg/mL RC or vehicle control (three wells
per treatment group). After 24 hours, 1X105 cells were seeded onto a BD BioCoat™
migration chamber (8 µm pore) plate (Corning, Tewksbury, MA) and treated with serum-
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free RPMI. Migration chambers were placed in a 24-well plate so that they hovered
above RPMI containing 10% FBS in order to create a gradient for cell migration. After 24
hours of incubation, migration chamber membranes were fixed for 10 minutes with 10%
formalin, stained with 2% crystal violet for 20 minutes, and rinsed 3 times with distilled
H2O. Non-migrating cells were removed from the upper surface of the membrane with a
cotton-tipped swab moistened with 1X PBS. The membrane was then mounted on a
microscope slide with Cytoseal™ XYL mounting medium (Richard-Allan Scientific™)
in order to evaluate the under surface of the membrane for migrated cells. Images were
captured with an Olympus BX41 light microscope using SPOTSOFTWARE (Diagnostic
Instruments, Inc., Sterling Heights, MI). The total number of migrating cells was
quantified in representative images per each membrane sample obtained 10X
magnification.

5.2.9 RNA isolation and quantitative RT-PCR
NB-1691 cells were treated with 10% ethanol vehicle control or 100µg/ml RC for
24 hours. RNA was extracted from cells using Trizol (Invitrogen, Carlsbad, CA) per
protocol utilizing acid-phenol extraction method. Following RNA extraction, up to 10µg
of RNA samples were then treated with DNAse (Thermo Fisher, Grand Island, NY) in
order improve purity of samples. RNA levels were quantified utilizing Nanodrop
(Thermo Scientific, Wilmington, DE).
Relative levels of mRNA were determined by quantitative real-time polymerase
chain reaction (qRT-PCR) using the Strategene Mx3005P real time PCR system (Agilent
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Technologies, La Jolla, CA). All values were normalized to the amplification of GAPDH.
The PCR primer sequences evaluated are listed in Table 5.1. The assays were performed
using the one-step 2X Brilliant SYBR Green qRT-PCR Master Mix Kit (Agilent
Technologies, Santa Clara, CA) containing both 200nM of forward primer and reverse
primer as well as 50ng total mRNA. The conditions for target mRNA amplification were
performed as follows: one cycle of 50°C for 30 minute; one cycle of 95°C for 10
minutes; 35 cycles each 95°C for 30 seconds, 55°C for one minute, and 72°C for 30
seconds.

5.2.10 Hypoxia Inducible Factor Transfection and Luciferase Assay
NB-1691 cells were plated in a 24 well plate at 8x104cells/well and were
transfected the following day with a reporter construct containing an inducible hypoxia
inducible factor (HIF) promoter (Qiagen, Valencia, CA) as well as non-inducible reporter
construct (negative control) and a constitutively active reporter construct (positive
control). Vectors were transfected using Lipofectamine® 2000 (Invitrogen, Carlsbad,
CA) as per manufacturer instructions. After 24 hours of transfection, the cells were then
treated with either ethanol vehicle control or 100µg/ml RC for 24 hours. Cells were then
washed with 1X PBS and lysed using 1X passive lysis buffer (Promega). Luciferase
activity was measured using the Dual-Luciferase® reporter assay system

(Promega)

according to the manufacture’s instructions. Light output was measured with a TD-20/20
Luminometer (Turner Designs, Sunnyvale, CA), and relative luciferase activity was
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calculated by firefly luciferase activity/renilla luciferase activity. Luciferase activity of
vehicle control treated cells were compared to RC treated cells.

5.2.11 Evaluation of Pyruvate Supplementation on the Effects of RC on NB-1691
Viability
In order to evaluate if media supplementation with pyruvate alters the outcomes
of RC treatment on NB-1691 cells, viability and growth were evaluated with trypan blue
exclusion, an MTS assay and a clonogenicity assay. Prior to performance of these assays,
NB-1691 cells were grown in media conditioned with 1mM of pyruvate. For MTS and
viability assays, cells were treated in suspension with 200µg/mL RC or ethanol +/- 1mM
pyruvate. Cells were then incubated for 24 hours and assays were performed. For
clonogenicity assays, 300 NB-1691 cells were allowed to adhere to the plate. Cells were
then treated to 200µg/mL RC +/- 1mM pyruvate throughout experiment. Cells were
allowed to grow for approximately three weeks in which colonies were established.
Colonies were then fixed, stained and quantified.

5.2.12 Evaluation of Nutrient Supplementation on the Effects of RC on NB-1691
Viability
All experiments were performed on 1X104 NB-1691 added to DMEM media
lacking pyruvate, glucose and glutamine. Cells were then treated with 200µg/mL RC or
ethanol vehicle control. Media was then additionally supplemented with either 25mM
glucose, 2mM glutamax or 0.4mM non-essential amino acids (NeAA). Treatment was
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added to cells in suspension and cells were then plated on a 96 well microtiter plate and
incubated for 24 hours. MTS assay was then performed to assess for viability.

5.2.13 Evaluation of Citric Acid Cycle Intermediates on the Effects of RC on NB-1691
Viability.
All experiments were performed on 2X105 NB-1691 cells which were treated with
200µg/mL RC or vehicle control +/- one of four citric acid cycle intermediates. Those
evaluated included: 5mM α-ketoglutarate (αkg), 5mM malate, 5mM succinate, or 5mM
isocitrate. Treatment was added to cells in suspension and cells were then incubated for
24 hours. Cells were washed with PBS, treated with trypsin, and viability was then
evaluated using trypan blue exclusion using a Vi-cell counter.

5.2.14 Evaluation of Metabolic Inhibitors on the effects of RC on NB-1691 Viability
NB-1691 cells were treated with one of three metabolic inhibitors including: 2deoxy-D-glucose (2DG) which is a glucose analog that inhibits glycolysis [12],
dichloroacetate (DCA) which inhibits pyruvate dehydrogenase kinase (PDK) which
drives cells to utilize mitochondrial respiration [13], or rotenone which inhibits oxidative
phosphorylation through inhibition of complex I in the mitochondrial electron transport
chain [14]. In order to evaluate the effects of glycolytic inhibition on RC, 1X104
NB-1691 were treated with 200µg/mL RC or ethanol +/- 11.1mM 2DG (equimolar to
glucose concentration in the media). Cells were treated in suspension and plated on a 96
well microtiter plate for 24 hours, following which an MTS assay was performed to
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assess for viability. In order to evaluate mitochondrial metabolism on the effects of RC,
2X105 cells were treated with 200µg/mL RC or ethanol +/- 20nM DCA, treated in
suspension. Trypan blue exclusion performed utilizing a Vicell counter was performed 24
hours after treatment to assess for viability. Finally, in order to evaluate oxidative
phosphorylation inhibition on the effects of RC, 2X105 cells treated with 200µg/mL RC
or ethanol +/- 50nM rotenone, treated in suspension for 24 hours. Trypan blue exclusion
performed utilizing a Vicell counter to assess for viability.

5.2.15 Lactate Dehydrogenase Activity Assay
NB-1691 cells were treated in microcentrifuge tubes in which 1X106 cells were
treated in suspension with 200µg/mL RC or ETOH for a total of two hours. Samples were
evaluated in triplicate. After two hours, samples were prepared per Lactate
Dehydrogenase (LDH) Activity Assay (Sigma Aldrich, St. Louis, MO) protocol. Cells
were homogenized in LDH Activity buffer and centrifuged at 10000 X g for 15 minutes
at 4oC. Samples were ran on a 96 well plate along with a positive control and NADH
standards (standard concentrations evaluated included: 0 (blank), 2.5, 5, 7.5, 10, and
12.5nmole/well). Following homogenization, 5µL of each soluble fraction of unknown
samples were added to 45µL of LDH assay buffer. To each sample and standard, 50µl of
master mix containing LDH assay buffer and LDH substrate mix was added. Samples
were allowed to develop in the dark at 37oC for 2-3 minutes and then samples were
evaluated on an Enspire® multimode automated plate reader (Perkin Elmer, Waltham,
MA) to determine the initial [(A450)intial] absorbance at a wavelength of 450nm. The plate
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was then incubated at 37oC in the dark and repeat measurements were obtained every
5-10 minutes. The samples were allowed to continue to develop until the absorbance
value of most active samples exceeded that of the highest NADH standard (12.5nmole/
well). The measurement prior to this was determined the “penultimate” or final [(A450)
final]

measurement. LDH Activity was determined by subtracting the blank value from

each standard and unknown value. The [(A450)final] was then subtracted from the [(A450)
intial]

and this value was compared to the standard curve to calculate the amount of NADH

generated by LDH over the evaluated time period. Results of samples treated with
ethanol were compared to those treated with RC.

5.2.16 Pyruvate Kinase Activity Assay
NB-1691 cells were treated in microcentrifuge tubes in which 5X105 cells were
treated in suspension with 200µg/mL RC or ETOH for a total of two hours. Samples were
evaluated in triplicate. After two hours, samples were prepared per Pyruvate Kinase (PK)
Activity Assay (Sigma Aldrich, St. Louis, MO) protocol. Cells were homogenized in PK
assay buffer and centrifuged at 15,000 X g for 10 minutes. Samples were ran on a 96 well
plate along with pyruvate standards (standard concentrations evaluated included: 0
(blank), 2, 4, 6, 8, and 10nmole/µL). Following homogenization, 5µL of each soluble
fraction of unknown samples were added to 40µL of PK assay buffer. To each sample and
standard, 50µl of master mix containing PK assay buffer, PK substrate mix, PK enzyme
mix and fluorescent peroxidase substrate mix was added. Samples were allowed to
develop for 2-3 minutes and then samples were evaluated on an Enspire® multimode
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automated plate reader (Perkin Elmer, Waltham, MA) to determine the initial [(A570)intial]
absorbance at a wavelength of 570nm. The plate was then incubated at room temperature
in the dark and repeat measurements were obtained every 5-10 minutes. The samples
were allowed to continue to develop until the absorbance value of most active samples
exceeded that of the highest pyruvate standard (10nmole/µL). The measurement prior to
this was determined the “penultimate” or final [(A570)final] measurement. PK Activity was
determined by subtracting the blank value from each standard and unknown value. The
[(A570)final] was then subtracted from the [(A570)intial] and this value was compared to the
standard curve to calculate the amount of pyruvate generated by PK over the evaluated
time period. Results of samples treated with ethanol were compared to those treated with
RC.

5.2.17 Nicotinamine Adenine Dinucleotide Quantification Assay
NB-1691 cells were treated in microcentrifuge tubes in which 8X105 cells were
treated in suspension with 200µg/mL RC or ETOH +/-1mM pyruvate for a total of two
hours. Samples were evaluated in triplicate. After two hours, samples were prepared per
Nicotinamine adenine dinucleotide (NAD+) Quantification protocol (Sigma Aldrich, St.
Louis, MO). Cells were pelleted and then homogenized in 400µL of NADH/NAD
extraction buffer. Samples were vortexed and then centrifuged at 13000 X g for 10
minutes. Samples were run on a 96 well plate along with NADH standards (standard
concentrations evaluated included: 0 (blank), 2, 4, 6, 8, and 10pmole/well). Following
homogenization, samples were then filtered through a 10kDa microcentrifuge cut-off spin
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filter (Thermo Scientific, Grand Island, NY). Then 50µL of each sample was plated on 96
well plate and then 100µl of master mix containing NAD+ cycling buffer and NAD+
cycling enzyme mix was added. Samples were allowed to develop for 5 minutes and then
10µL of NADH developer was added to each well to convert NAD to NADH. Samples
were allowed to develop at room temperature from 1-4 hours in which measurements
were obtained on an Enspire® multimode automated plate reader (Perkin Elmer,
Waltham, MA) to determine the absorbance at a wavelength of 450nm (A450) to assess for
a total level of NADH and NAD+ together. The blank value was subtracted from each
standard and unknown value and this value was compared to the standard curve to
calculate the amount of NAD (NAD+ plus NADH) generated. This was then was
compared between samples treated with ethanol and RC.

5.2.18 Evaluation of RC treatment of Disseminated Neuroblastoma In Vivo
Twenty 6-week-old non-obese diabetic severe combined immunodeficient (NOD
SCID) mice were pretreated for three days with RC (100 mg/kg) or ethanol vehicle
supplemented into drinking water. A total of 1X106 NB-1691 cells were injected via
lateral tail vein to model a disseminated disease state. Mice were evaluated daily, and
water was replaced with appropriate treatment every 48 hours. All mice were euthanized
38 days following tumor injection as mice began to exhibit decreasing weight. At the
time of euthanasia, the lungs were injected with india ink and then preserved in Fekete’s
solution. All remaining organs were preserved in 10% formalin or flash frozen in liquid
nitrogen. Formalin-fixed paraffin-embedded livers and kidneys were further analyzed
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histologically by H&E staining. Representative images of H&E-stained liver and kidney
sections were taken using an Olympus BX41 light microscope using SPOTSOFTWARE
and metastatic foci from 10X images were quantified. (Diagnostic Instruments, Inc.).

5.2.19 Statistical analysis
All results were analyzed using either a two-tailed student’s t-test with one-way
analysis of variance (ANOVA) or a two-ANOVA. Statistical outliers were identified
utilizing a Grubb’s test. All graphs were made and statistical analysis was performed
using GraphPad Prism Software (Prism, GraphPad Software, Inc., San Diego, CA).

5.3 Results
5.3.1 In Vitro effects of RC on Neuroblastoma
Both cell lines were treated with 200µg/mL RC or ethanol vehicle control for 24
hours. Upon microscopic analysis, RC treated cells in both lines were noted to have a
significant proportion of dead or abnormal appearing cells. Morphological changes of RC
treatment consisted of more rounded appearing cells, which were less adherent (Fig 5.1).
Further, cells treated with RC were associated with the development of cytoplasmic
vacuoles within several hours of treatment.

5.3.2 Cytotoxic Effects on RC on Neuroblastoma In Vitro
In order to quantify the cytotoxic effects of RC, both cell lines were treated with
graduated doses of RC raging from 50µg/ml to 200µg/mL over 72 hours. Strikingly, the
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viability of NB-1691 was reduced by more then 50% upon RC treatment. SK-N-AS cells,
in contrast, exhibited an approximate 40% decrease in viability upon RC treatment (Fig
5.2A, B). The cytotoxic effects were noted to be greater upon application of RC treatment
while cells were in suspension compared to RC treatment following adherence to the
culture plate, especially in the NB-1691 cells. An MTS calorimetric proliferation assay
performed on both cell lines following treatment with graduated doses of RC revealed an
approximate 20-25% reduction in proliferation compared to vehicle control upon RC
treatment (Fig 5.2C, D).

5.3.3 RC effects on Neuroblastoma Migration and Proliferation
The growth and proliferation of neuroblastoma cells was also markedly affected
by RC therapy. A scratch wound assay performed in both cell lines revealed a reduction
in cell migration and wound healing upon RC treatment compared to ethanol vehicle
control (Fig 5.3A). Additionally, a clonogenic assay of NB-1691 cells exposed to
continuous 50µg/mL RC +/- 5gy radiation treatment resulted in a significant reduction in
the number of established colonies (p<0.0001). Strikingly, upon RC treatment, no
colonies were observed, regardless of radiation exposure (Fig 5.3B). However, no
difference in cellular migration, assessed utilizing Transwell migration inserts, was
observed upon RC treatment on NB-1691 cells in vitro compared to vehicle control.

5.3.4 Evaluation of the Cytotoxic Effects of RC Compared to Dox
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The cytotoxic effects of RC were compared to that of Dox, a common drug
utilized in multi-agent treatment for high risk neuroblastoma. The cytotoxic effects of RC
treatment was observed to be much greater than that observed with Dox treatment in
NB-1691 cells, especially upon RC treatment with cells in suspension. In contrast, SK-NAS cells were more susceptible to Dox treatment compared to RC treatment (Fig 5.4A,
B).

5.3.5 RC Effects on Gene Expression Regulating Cellular Differentiation
Inhibitor of DNA (Id) genes are known to play a role in cellular differentiation
[7,9]. Reduction in the expression of ID 1, 2 and 3 was observed upon RC treatment. ID1
and ID3 expression was significantly reduced (p<0.05) upon treatment with RC
compared to ethanol vehicle control (Fig 5.5A).

5.3.6 RC Effects on HIF and HIF Related Gene Expression
In order to evaluate potential genes related to the Warburg Effect including those
involved with nutrient uptake and cellular metabolism, qRT-PCR was performed
evaluating the mRNA expression of HIF-1α subunit and several HIF-1 downstream
targets including genes involved in glycolysis (HK2, PKM2), cellular transport (MCT1,
SLC7A11, GLUT1) and angiogenesis (VEGFa, VEGFa165). This revealed a significant
up-regulation of HIF-1α expression upon RC treatment (p<0.05). Additional upregulation of PKM2, VEGF and MCT1 was also observed (Fig 5.5B). Given the
increased expression of HIF-1α, further confirmation of alterations in HIF-1 activity was
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performed. NB-1691 cells transfected with a HIF-luciferase reporter element exhibited a
significant up-regulation in HIF promoter activity upon RC treatment (p=0.0094)
compared to vehicle control, which corroborated with qRT-PCR findings (Fig 5.5C).

5.3.7 Pyruvate Rescues Cells from Cytotoxic Effects of RC
Upon the supplementation of media with pyruvate, the viability of NB-1691 was
rescued from the cytotoxic effects of RC. This was confirmed utilizing an MTS assay,
trypan blue exclusion and a clonogenicity assay. Upon viability evaluation using trypan
blue exclusion, RC resulted in a 69% reduction in viability without pyruvate, while the
addition of pyruvate with RC resulted in only 16.6% reduction in viability, compared to
vehicle control. While there was still a significant reduction in viability of pyruvate with
RC compared to vehicle control (p=0.0361), an improvement in viability upon pyruvate
with RC compared to treatment of RC without pyruvate was also significant (p<0.001,
Fig 5.6B).
MTS assay further supported these results as RC treatment alone resulted in
approximate 60% reduction in absorbance compared to control while the addition of RC
with pyruvate resulted in a 40% reduction in absorbance. Ethanol treatment resulted in a
signficant reduction in absorbance, regardless of pyruvate supplementation (p<0.01),
however the addition of pyruvate to RC resulted in a significant improvement in
absorbance compared to RC alone (p<0.01, Fig 5.6A).
Finally, a clonogenicity assay performed evaluating colony growth and formation
following treatment with RC supplemented with pyruvate. Treatment with vehicle
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control, regardless of the addition of pyruvate, resulted in the development of 70-125
colonies per plate. In contrast, treatment with RC alone resulted in no colony formation,
while pyruvate addition lead to a significant increase in the number of colonies observed
per plate (an average of 43 colonies per plate, p<0.01, Fig 5.6C).

5.3.8 Evaluation of Nutrient and Metabolic Intermediate Supplementation on the Effects
of RC Treatment.
An MTS assay was performed on NB-1691 evaluating the effects of glucose,
NeAA and glutamax supplementation. No significant difference upon the addition of
glucose (Fig 5.7A), NeAA (Fig 5.7B) or glutamax (Fig 5.7C) was observed upon RC
treatment alone compared to RC treatment supplementation with any of these nutrients.
The supplementation of RC treatment with citric acid cycle intermediates,
including malate, isocitrate, αkg and succinate, was performed and trypan blue exclusion
was utilized to establish the effect. Upon the addition of malate (Fig 5.8B), succinate (Fig
5.8C) or isocitrate (Fig 5.8D) to RC treatment, no improvement in viability was observed.
In contrast, cells treated with RC alone exhibited 36% viability compared to RC treated
cells supplemented with αkg which displayed 94% viability. This rescue of the cytotoxic
effects of RC upon αkg supplementation compared to RC treatment alone was significant
(p<0.001, Fig 5.8A).

5.3.9 Effect of Metabolic Inhibitors on RC Treatment upon NB-1691 Cells In Vitro
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The effects of glycolysis inhibition on the effects of RC was evaluated by
treatment with 2DG followed by an MTS assay. Upon treatment of NB-1691 cells with
2DG, a significant reduction in the absorbance of cells treated with 2DG and ethanol
compared to ethanol alone was observed (p<0.001). Despite this, cells treated with 2DG
and ethanol still displayed greater absorbance than cells treated with 2DG and RC
(p<0.001). Additionally, 2DG treatment with RC did result in a slight decrease in
absorbance compared to RC treatment alone (p<0.01, Fig 5.9A).
Viability was evaluated upon the inhibition of PDK in the setting of RC treatment
utilizing DCA. DCA did not result in decreased viability upon cells treated with ethanol
(Fig 5.9B). Additionally, the viability of RC treatment remained unchanged upon the
addition of DCA as well.
Viability was also evaluated upon the inhibition of oxidative phosphorylation in
the setting of RC treatment utilizing rotenone. Similar to DCA, rotenone did not result in
reduced viability of NB-1691 cells treated with ethanol (Fig 5.9C). Further, rotenone
treatment did not further reduce the viability of cells treated with RC.

5.3.10 Evaluation of RC Effect on PK Activity
PK activity was observed to be significantly increased upon treatment with
200µg/mL RC compared to ethanol treated NB-1691 cells following two hours of
treatment (p=0.0081). Ethanol treated cells exhibited an approximate 48nM/min/mL rate
of PK activity while RC treated cells displayed an approximate 65nM/min/mL rate of PK
activity (Fig 5.10A).
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5.3.11 Evaluation of RC Effect on LDH Activity
LDH activity was observed to be significantly reduced upon treatment with
200µg/mL RC compared to ethanol treated NB-1691 cells following two hours of
treatment (p=0.0196). On average ethanol treated cells exhibited 24mU/mL rate of LDH
activity while RC treated cells had a 16mU/mL rate of LDH activity (Fig 5.10B).

5.3.12 Evaluation of RC Effects on Total Cellular NAD Levels
A significant reduction in the total NAD (NAD++NADH) levels was observed
upon treatment with 200µg/mL RC in NB-1691 cells following two hours of treatment
(p<0.001, Fig 5.10C). RC treated cells had about 75% less total NAD then ethanol treated
cells. The total amount of NAD was increased upon the addition of 1mM pyruvate to
cells resulting in no significant difference between ethanol and RC treatment groups in
the presence of pyruvate.

5.3.13 In Vivo Evaluation of RC Effects on Disseminated Neuroblastoma
The effect of RC on prevention of metastatic when decreasing weights were
observed in mice (Fig 5.11A). At the time of euthanasia, there was no difference in the
weight of mice between treatment groups (Fig 5.11B). Upon necropsy, the greatest
burden of metastatic foci was observed in the liver and kidneys in both treatment groups
and there was no gross difference observed in metastatic establishments of tumor
between treatment groups. There were no differences in the weights of organs, including
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liver, kidney, spleen, heart and lungs, between treatment groups (Fig 5.12A). The liver
and kidneys were further evaluated histologically. The average number of metastatic foci
observed in representative 10X images of liver and kidneys for all animals again revealed
no difference in tumor burden between mice treated with ethanol and RC (Fig 5.12A, B).

5.4 Discussion
Neuroblastoma remains one of the deadliest childhood cancers. Outcomes of
aggressive variants of this disease result in high mortality rates and investigation into
novel treatment methods may lead to improved outcomes for this patient population in
the future. Through this work, we identified that RC results in the striking development
of neuroblastoma cytoxicity in vitro. Further, RC treatment results in reduced growth and
proliferation of these cells. These cytotoxic effects are likely secondary to metabolic
derangements afforded by treatment with this extract resulting in cell death. While there
was no improvement in outcomes observed upon RC treatment in a disseminated model
of neuroblastoma, given the in vitro findings observed, RC still offers therapeutic
potential for the treatment of neuroblastoma.
Upon investigation of RC treatment on neuroblastoma cells in vitro, two cell
culture lines were evaluated, one which was MYCN amplified (NB-1691) and another
without MYCN amplification (SK-N-AS). MYCN is a critical oncogene for determining
the aggressiveness of a patient’s tumor, as amplification of MYCN is associated with
more advanced and aggressive disease as well as poorer outcomes [1-4]. To this end,
while RC treatment resulted in reduced viability in both cell lines, surprisingly the effects
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of RC were enhanced upon treatment on NB-1691 cells. These effects were even more
pronounced upon treatment of cells prior to adherence to the culture dish. In contrast, SKN-AS cells were more susceptible to the effects of Dox, a common chemotherapeutic
agent utilized for the treatment of neuroblastoma in the clinical setting [1,5] while
NB-1691 were much less sensitive to Dox. Given these findings, our further efforts into
the investigation of the effects of RC on neuroblastoma were focused on the NB-1691
cell line given that these cells remained more susceptible to RC.
In addition to the cytotoxic effects that RC conferred upon neuroblastoma cells,
RC also resulted in reduced growth as well as alterations in genetic expression. RC
resulted in a significant reduction in the expression of Id genes. Numerous types of
cancers have revealed alteration in Id gene expression upon RC treatment [7,9]. As Id
genes are associated with cellular differentiation, RC treatment may also result in a
reduction in the patterns of cell growth and differentiation resulting in a less aggressive
tumor phenotype.
RC treatment resulted in a rapid cytotoxicity, in which reduced growth and
increased cell death were observed within 24 hours of treatment. Further, alterations in
genetic expression and enzymatic activity were observed in as little as two hours
following treatment. Upon RC treatment of NB-1691 in culture, cells began to develop
cytoplasmic vacuoles, suggestive of cellular damage and/or autophagy, within several
hours. We hypothesized that the causes for these effects could be attributable to nutrient
deficiencies, oxidative damage or derangements to cellular metabolism.
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In order to evaluate the means to which RC exerts it’s cytotoxic effects on
NB-1691 cells, a variety of metabolic nutrients and intermediates were provided upon RC
treatment. Interestingly, pyruvate as well as αkg resulted in significant rescue in cell
viability in the setting of RC treatment. The addition of glucose, NeAA or glutamax, as
well as other citric acid cycle intermediates, failed result in any appreciable improvement
in cell viability upon RC treatment. This reveals that the effects of RC are, at least
partially, reversible and are dependent upon the availability of key nutrients to prevent the
development of cell death.
The Warburg effect states that the growth of rapidly proliferating cells, such as
cancers, are more dependent on glycolysis, even in aerobic conditions. This is achieved
through enhanced cellular glucose uptake as well as promotion of glycolysis over
mitochondrial dependent cellular respiration [15-18]. HIF is believed to play a key role in
the Warburg Effect as a “switch” in cancer development as it promotes glycolysis as
favored cellular metabolism [19, 20]. While we observed that HIF expression and it’s
transcriptional activity are increased upon RC treatment, these results are likely
secondary to the cellular stress imposed by RC treatment.
HIF is a key regulator of cellular metabolism and in cancer cells enhances
glycolytic activity and reduces mitochondrial respiration. To this end, elevations in HIF
activity typically result in enhanced the activity of LDH [21, 22], furthering anaerobic
metabolism and restoring cellular levels of NAD for continued use in glycolysis [23].
Despite elevated HIF expression observed upon RC treatment, the activity of LDH was
noted to be decreased and PK activity was observed to be increased. Additionally, the
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total cellular levels of NAD were significantly reduced upon RC treatment compared to
vehicle treated cells. Therefore RC treatment potentially prevents optimal functioning of
cellular metabolism that maintains the Warburg Effect as changes in enzymatic activity
observed upon RC treatment drives the cells away from glycolysis. Further, given
reduced cellular NAD levels observed upon RC treatment, effective cellular metabolism
can not be continued efficiently to maintain cellular growth and viability. Future work
will focus on further defining the mechanism to which RC affects the cellular metabolism
of neuroblastoma and it’s association with cellular viability.
Given the observation of the effects that RC exerts on NB-1691 cells, further
investigation into the in vivo effects of RC on neuroblastoma was performed. To this end,
a disseminated model of neuroblastoma was investigated as RC has previously been
shown to prevent the establishment of both primary tumors and metastastic lesions [6,8].
Mice were provided RC enterally and then NB-1691 were injected via the lateral tail vein
to create a disseminated disease state. Despite positive outcomes upon RC treatment
observed upon investigations of other tumors, such as melanoma, we did not observe any
difference in the establishment of metastatic neuroblastoma upon RC treatment. Several
reasons may have contributed to these results. First, as NB-1691 cells are derived from
human neuroblastoma, immunodeficient NOD SCID mice were utilized. RC is known to
be immuno-modulatory and through the use of NOD SCID mice, the benefits of the
immunologic changes resulting from RC treatment may have been lost. Secondly, as
neuroblastoma cells can be rescued from the cytotoxic effects of RC upon
supplementation with nutrients such as pyruvate, the availability of these nutrients
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systemically may prevent RC from affecting circulating neuroblastoma cells. Alternative
evaluation of orthotopic neuroblastoma or evaluation of alternative neuroblastoma cell
lines in an immunocompetent mouse may result in improved outcomes upon RC
treatment.

5.5 Conclusion
Through this work, dramatic cytotoxic and anti-proliferative effects following RC
treatment on neuroblastoma in vitro were observed. Strikingly these effects are more
pronounced in NB-1691 cells, despite it’s MYCN amplified status. The in vitro effects of
RC appear to result from alterations in the metabolic functioning of the cell resulting in
rapid cytotoxicity. These findings are promising as a novel adjuvant therapyfor
neuroblastoma. Despite our in vitro findings, RC treatment failed to result in an improved
outcome upon treatment in a disseminated model of neuroblastoma in vivo. However, RC
treatment may still prove to be efficacious for the treatment of neuroblastoma as it may
improve outcomes for the treatment of solid tumors or as an adjunct therapy to other
chemotherapeutic agents. Further work is required to assess the therapeutic benefits of
Rhodiola plant extracts for the treatment of neuroblastoma.
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5.6 Figures

Figure 5.1. Morphological Effects of RC Treatment on Neuroblastoma Cells In Vitro. Phase
contrast images of live neuroblastoma cells, both SK-N-AS (A, B) and NB-1691 (C, D) cell lines,
were performed following 24 hours of ethanol vehicle (A, C) and RC treatment (B, D).
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Figure 5.2. Cytotoxic Effects of RC on Neuroblastoma In Vitro. A) 72 hour viability evaluated
with trypan blue exclusion on NB-1691 (black) and SK-N-AS (red) cells following treatment
with RC, dose including 0, 50, 100, 200µg/mL upon treatment in suspension. B) 72 hour viability
evaluated with trypan blue exclusion on NB-1691 and SK-N-AS cells treated with 0, 50, 100,
200µg/mL RC following plate adherence. C) MTS assay performed on SK-N-AS cells treated
with 0, 10, 50, 100, and 200µg/mL RC in suspension. Results presented as absorbance relative to
vehicle control treated cells following 24 hours of treatment. D) MTS assay performed on
NB-1691 cells treated with 0, 10, 50, 100, and 200µg/mL RC in suspension. Results presented as
absorbance relative to vehicle control treated cells following 24 hours of treatment. Error Bars
indicate +/- standard error of the mean, *=p<0.05, **=p<0.01
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Figure 5.3. Evaluation of RC’s Effect on Migration and Growth on Neuroblastoma In Vitro
A) Scratch wound was created in confluent monolayer of SK-N-AS and NB-1691 then treated
with either ethanol or 200µg/mL RC. Representative images following 4 and 72 hours of
treatment with either vehicle control or RC are shown. Red and blue lines outline borders of
growth within scratch wound. B) Clonogenicity evaluation of NB-1691 treated with 50µg/mL RC
or ethanol vehicle control +/- 5Gy radiation. RC treatment was applied continuously. C) The
average number of cells treated with either ethanol or 100µg/mL RC that migrated through
transwell migration wells quantified in each representative 10X field. Error Bars indicate +/standard error of the mean, *=p<0.05, **=p<0.01, ****=p<0.0001.
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Figure 5.4. Evaluation of RC vs Dox treatment on Neuroblastoma In Vitro. 72 hour viability
evaluated using trypan blue exclusion of SK-N-AS (A) and NB-1691 (B) cells performed
following treatment with 200µg/mL RC both before and after adherence to the plate. Results were
compared to 10µg/mL Dox treatment. Results presented as viability relative to ethanol control
treated cells. Error Bars indicate +/- standard error of the mean, *=p<0.01, **=p<0.001.
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Figure 5.5. Effects on Gene Expression upon RC treatment in NB-1691 In Vitro. A)
Quantitative RT-PCR was performed from RNA extracted from NB-1691 cells treated with
100µg/mL RC or ethanol vehicle control for 24 hours. Changes in mRNA levels normalized to
GAPDH expression of ID 1, ID 2, and ID 3 gene expression. B) Changes in mRNA levels
normalized to GAPDH expression of HIF-1 targets including HIF1-α, HK2, PKM2, VEGF,
VEGFa165, MCT1, SLC7A11 and GLUT1. C) NB1691 cells transfected with luciferase reporter
HIF-1 promoter and treated with 100µg/mL RC or ethanol vehicle for 48 hours. Luciferase
activity was evaluated and relative luciferase activity is reported. Error Bars indicate +/- standard
error of the mean, *=p<0.05 and **=p<0.01.

98

Figure 5.6 Evaluation of the Effects of Pyruvate Upon RC Treatment on Neuroblastoma. A)
MTS assay performed on NB-1691 cells treated with 200µg/mL RC or ETOH +/- Pyruvate
(1mM) following 24 hours of treatment. B) Assessment of viability utilizing trypan blue
exclusion on NB-1691 cells treated with 200µg/mL RC or ETOH +/- Pyruvate. C) Clonogenicity
evaluation of NB-1691 treated with 50µg/mL RC or ethanol vehicle control +/- 1mM Pyruvate.
RC treatment was applied continuously and plates were evaluated for the development of colony
formation over three weeks. Following this, cells were fixed and stained with crystal violet and
total colonies formed were quantified. Error Bars indicate +/- standard error of the mean,
*=p<0.05.
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Figure 5.7. Evaluation of Nutrient Supplementation on RC Effects on Neuroblastoma
Viability In Vitro. All experiments were performed on 1X104 NB-1691 cells treated with RC or
ethanol in suspension +/- listed nutrient in DMEM lacking pyruvate, glucose and glutamine. Cells
were incubated for 24 hours and then an MTS assay was performed to assess for cell viability. A)
Evaluation of the effects of glucose (25mM) on RC treatment. B) Evaluation of the effects of
non-essential amino acids (0.4mM) on RC treatment. C) Evaluation of the effects of glutamax
(2mM) on RC treatment. Error Bars indicate +/- standard error of the mean, *=p<0.05.
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Figure 5.8. Evaluation of Citric Acid Cycle Intermediate Supplementation on RC Effects on
Neuroblastoma Viability In Vitro. All experiments were performed on 2X105 NB-1691 cells
pre-conditioned in pyruvate (1mM) containing medium. Cells were treated with 200µg/mL RC or
vehicle control +/- 5mM α-ketoglutarate (A), +/- 5mM malate (B), +/- 5mM succinate (C), +/5mM isocitrate (D) in suspension and incubated for 24 hours. Viability was evaluated using
trypan blue exclusion using a Vi-cell counter. Error Bars indicate +/- standard error of the mean,
*=p<0.05.
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Figure 5.9. Effect of Metabolic Inhibitors on RC Treatment upon NB-1691 Cells In Vitro. A)
1X104 cells treated with 200µg/mL RC or ethanol +/- 11.1mM 2-deoxy-D-glucose (2DG), treated
for 24 hours and MTS assay was performed to assess for viability. B) 2X105 cells treated with
200µg/mL RC or ethanol +/- 20nM dichloroacetate (DCA), treated in suspension for 24 hours.
Trypan blue exclusion performed utilizing a Vicell counter was utilized to assess for viability. C)
2X105 cells treated with 200µg/mL RC or ethanol +/- 50nM Rotanone, treated in suspension for
24 hours. Trypan blue exclusion performed utilizing a Vicell counter was utilized to assess for
viability.
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Figure 5.10 RC Effects on Metabolic Enzyme Activity and Metabolic Intermediate Levels.
A) Pyruvate Kinase Activity levels evaluated upon NB-1691 treated for two hours with either RC
200µg/mL or ETOH. Results show both PK activity (nM/min/mL) for each sample as well as PK
activity over time. B)Lactate Dehydrogenase Activity levels evaluated upon NB-1691 treated for
two hours with either RC 200µg/mL or ETOH. Results shown include LDH activity (mU/mL) for
each sample as well as LDH activity over time. C) NAD Quantification Assay performed in
NB-1691 cells treated with 200µg/mL RC or ETOH +/-1mM pyruvate for two hours in which
total NAD+NADH levels were quantified. Error bars represent +/- standard error of the mean,
*=p<0.05.
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Figure 5.11. Evaluation of the In Vivo Efficacy of RC Treatment of Disseminated
Neuroblastoma. A) Graphic representation of the weight changes of mice treated with 100mg/kg
RC or ETOH with disseminated NB-1691 over time. Arrows represent dates of RC treatment
initiation (RC) and tail vein injection (TVI). B)Weight change at time of euthanasia of mice
treated with 100mg/kg RC or ETOH. Error bars represent +/- standard error of the mean.
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Figure 5.12. Outcomes of RC treatment in a disseminated in vivo neuroblastoma model. A)
Proportional total weights of organs collected at time of euthanasia including from mice treated
with either 100mg/kg RC or ETOH. Organs represented include liver, kidney, spleen, lung and
heart. B) Average number of metastatic lesions established in kidneys present within each 10X
field. Representative 10X images of kidney samples from each treatment group shown, arrows
represent metastatic lesions. C) Average number of metastatic lesions established in livers present
within each 10X field. Representative 10X images of liver samples from each treatment group
shown, arrows represent metastatic lesions. Error bars represent +/- standard error of the mean
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5.7 Tables
Table 5.1 - Primers Utilized in qRT-PCR. List of primers utilized for qRT-PCR to evaluate the
effects of RC treatment of NB-1691 cells on genetic expression.
Gene

Forward Sequence

Reverse Sequence

5‘-TGCACCACCAACTGCTTAGC-3’

5‘-GGCATGGACTGTGGTCATGAG-3’

ID1

5‘-CCAGAACCGCAAGGTGAG-3’

5‘-GGTCCCTGATGTAGTCGATGA-3’

ID2

5’-GACAGAACCAGGCGTCCA-3’

5’-AGCTCAGAAGGGAATTCAGATG-3’

ID3

5’-CATCTCCAACGACAAAAGGAG-3’

5’-CTTCCGGCAGGAGGGTT-3’

HIF1

5’-CTCACCAGACAGAGCAGGAA-3’

5’-TGCGAAGCTATTGTCTTTGG-3’

HK2

5’-TCGAGTACATGGGCATGAAGG-3’

5’-ACTTGAGGAGGATGCTCTCGT-3’

PKM2

5’-CCACTTGCAATTATTTGAGGAA-3’

5’-GTGAGCAGACCTGCCAGACT-3’

MCT1

5’-GTCATTGGAGGTCTTGGGCT-3’

5’-GCCAATGGTCGCCTCTTGTA-3’

SLC7A11

5’-GGCAACCGCGTAATACTTG-3’

5’-TTGCAAGCTCACAGCAATTC-3’

GLUT1

5’-GGTTGTGCCATACTCATGACC-3’

5‘CAGATAGGACATCCAGGGTAGC-3’

VEGFa

5’-CCACGTCAGAGAGCAACATC-3’

5’-TCTCCTATGTGCTGGCTTTG-3’

5’-ATCTTCAAGCCATCCTGTGTGC-3’

5’-CAAGGCCCACAGGGATTTTC-3’

GAPDH

VEGFa165
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CHAPTER 6
CONCLUSION

6.1 General Discussion
Cancer remains one of the leading cause of death in the United States today.
While significant improvements to commonly used treatment agents as well as creation
or identification of novel therapeutic options have been made, the mortality rates of
cancer continues to remains high. Further, it’s treatments are limited by the toxicities
associated with the many of these chemotherapeutic agents. Development and evaluation
of novel methods to treat various forms of cancer may lead to improved survival as well
as reduced off target side effects and their associated morbiditities. This work sought to
evaluate novel treatment methods for several types of chemo-resistant cancer both in
vitro and in vivo.

6.2 Utilization of PolyMPC for Cancer Therapeutics
PolyMPC produgs have previously been shown to improve survival upon the
treatment of a murine model of breast cancer in immunocompetent mice. While these
findings were promising, the safety of the scaffold polyMPC polymer, as well as
evaluation of polyMPC prodrugs (polyMPC-Dox), had yet to be evaluated in a human
cancer model. Through this work we observed that polyMPC polymers were extremely
safe for systemic administration in mice. Limits to therapeutic administration of the
polymer were secondary to the viscosity of the polymer solution and the inability to
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further dilute higher doses of polymer effectively. No appreciable side effects were
observed following administration of large doses of polyMPC. Investigation of the
therapeutic efficacy of polyMPC-Dox upon treatment of a human ovarian tumor in NOD
SCID mice further confirmed the prior investigation of polyMPC-Dox in
immunocompetent mice. Mice treated with polyMPC-Dox displayed increased tumor
uptake of Dox. Additionally, treatment with polyMPC-Dox resulted in improved survival
of mice compared to control and free Dox treated mice. In comparison to doxil, an
alternative Dox formulation, treatment tolerance and survival was much improved in
mice treated with polyMPC-Dox.
Further investigation to improve targeting of polyMPC directly to tumors was
also evaluated. Mesenchymal stem cells, which have inherent tumoritropic capabilities,
were investigated as a vehicle to improved targeted delivery of polyMPC to tumor. We
observed that polyMPC can be stably loaded with polyMPC and that the in vivo
migratory capabilities of these cells were unaltered.

6.3 Utilization of Rhodiola Extract for the Treatment of Cancer
RC is an adaptogenic phytochemical that has been observed to have anti-tumor
properties, observed both in vitro and in vivo. Given these findings, we sought to evaluate
the effects of RC on two aggressive forms of cancer derived from the neural crest. For
both neuroblastoma and melanoma, we observed that RC lead to reduced viability,
growth and proliferation in vitro. Further investigation into the mechanism to which RC
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exerts it’s cytotoxic effects upon neuroblastoma treatment revealed that RC resulted in
changes in the metabolic activity of cells, likely resulting in cell death.
Upon evaluation of both cancers in a disseminated model to mimic metastatic
disease in vivo, RC lead to reduced establishment of pulmonary melanoma lesions,
although no difference in the establishment of neuroblastoma lesions was observed. Upon
investigation of the topical application of RC on subcutaneous melanoma lesions, tumors
were observed to grow more radially and tumors displayed reduced mitotic activity.

6.4 Conclusion
Through this thesis, I have evaluated alternative treatment options for the several
aggressive and chemo-resistant forms of cancer. Two broad approaches were evaluated
for this work in which both polyMPC prodrugs and Rhodiola based plant extracts were
utilized to treat cancer. Both polyMPC prodrugs and RC have the potential to broaden our
arsenal of anti-cancer agents that be to be employed in humans for the treatment of
cancer in the future.
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